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Abstract 
Chronic inflammatory joint diseases like rheumatoid arthritis (RA) remain one of the 
world's major health problems. Conventional anti-arthritic medicines like 
non-steroidal anti-inflammatory drugs (NSAIDs) and glucocorticoids are not suitable 
for long term use because they have a propensity to produce gastrointestinal 
disturbances and the latter may also cause other severe side effects. Therefore, an 
effective anti-arthritic drug with less adverse effects should be developed. 
There has been growing interest in the therapeutic uses of traditional Chinese 
medicines (TCM). In fact, TCM have been used to treat different kinds of diseases 
and symptoms such as arthritis for thousands years in Asia. However, scientific 
evaluation of the therapeutic efficacy and mechanisms of actions of many of the TCM 
are still inadequate. Animal models that mimic human disease conditions are very 
useful for preclinical studies of metabolism, toxicity and other pharmacological 
properties of these drugs. 
The Institute of Chinese Medicines of the Chinese University of Hong Kong has 
produced a Lingzhi and Sen Miao San capsule (LS), which is composed of 
Ganoderma lucidum, Cortex Phellodendri, Atractylodisa Rhizoma and Radix 
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Achyranthis Bidentatae. These constituents of LS are reported to have 
anti-inflammatory and analgesic effects, but the efficacy of LS in treatment of 
arthritic diseases is unknown. Therefore, the aim of this study was to evaluate the 
anti-arthritic property of LS in an animal model of arthritis induced by injection of 
Freund's complete adjuvant (FCA) into rat knees. LS was administered into rats by 
intra-articular, oral or intra-peritoneal route. Extension angle, size and blood flow of 
knee joints were measured to provide indexes of algesia, oedema, and hyperaemia, 
respectively. Histological scores on the extent of cell infiltration, tissue proliferation, 
and erosions of cartilage and bone in the knee joints were used as additional indexes 
of the arthritis condition. 
Single unilateral injection of FCA produced significant oedema, algesia, hyperaemia, 
immune cell infiltration, synovial tissue proliferation, and erosions of cartilage and 
bone in ipsilateral FCA-injected (test) knees compared with contralateral 
saline-injected (control) knees. Ipsilateral intra-articular injection of LS (2.5 
mg/kg/day) for 2 consecutive days after the induction of arthritis had no effect on the 
arthritis symptoms. Similarly, oral administration of LS (500 mg/kg/day and 1000 
mg/kg/day) for 7 days after the induction of arthritis did not improve the arthritis 
symptoms. The same negative finding was obtained with oral administration of LS 
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(500 mg/kg/day of LS) extended to 13 days. It is uncertain whether further extension 
of the oral treatment period of LS could have antiarthritic effects; this will have to be 
tested in a more chronic model of arthritis as the present monoarthritis model showed 
signs of resolution from 14 days onward. 
Interestingly, oral administration of LS (500 mg/kg/day) for 7 days before induction 
of arthritis (prophylactic treatment) and 7 days after induction of arthritis (therapeutic 
treatment) suppressed oedema (P < 0.05) and hyperaemia (P < 0.01) in the inflamed 
knees. Moreover, histological examination showed that this protocol of oral 
administration of LS reduced immune cell infiltration {P < 0.001 for both), and 
erosions of cartilage and bone (P < 0.001 for both) in the inflamed knees. Similarly, 
intra-peritoneal injection of LS (50 mg/kg/day) for 7 days before and 7 days after 
induction of arthritis suppressed oedema (P < 0.001), pain {P < 0.05), hyperaemia (P 
< 0.01), and synovial tissue proliferation (P < 0.05) in the inflamed knees. These 
findings suggest a combination of 7 days prophylactic treatment plus 7 days 
therapeutic treatment with intra-peritoneal or oral LS could provide significant 
anti-arthritic effects. 
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In conclusion, this study successfully produced discrete monoarthritis in the rat knee 
joint that shared several clinical and pathological features of the human disease, and 
this provided a useful platform for the testing of potential new antiarthritic agents like 
LS. Intra-articular injection of LS was found to be inappropriate for treatment of 
arthritis as intra-articular injections of two doses of LS did not alleviate the arthritis 
symptoms but produced further damage of the inflamed joints leading to more severe 
inflammation. Oral treatment with LS for 7 days or 13 days after the induction of 
arthritis also failed to produce significant anti-arthritic effect. However, a combination 
of 7 days prophylactic treatment plus 7 days therapeutic treatment with 
intra-peritoneal or oral LS provided significant anti-arthritic effects. These findings 
suggest LS can be administered intraperitoneal!y or orally to treat joint inflammation; 
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1.1 Prevalence of arthritis 
Inflammation, which is the response of an organism to noxious stimuli, is comprised 
of two major types of tissue reaction; acute and chronic. Acute inflammation is 
characterized by a rapid and short-lived response with classical signs of heat, redness, 
oedema, pain and loss of function resulting from a series of major cellular and 
biochemical events at the tissue level including changes in vascular flow and caliber, 
increased vascular permeability and leucocyte exudation. Chronic inflammation is a 
prolonged response, taking longer time to develop and with a longer duration than the 
acute one. The tissue is infiltrated by mononuclear cells, mainly macrophages, 
lymphocytes and the effector cells of the lymphocyte lineage. Moreover, there is 
destruction of normal host tissues associated with proliferation of fibroblasts and in 
many cases small blood vessels (Salisbury et aL, 1994). 
Arthritis is inflammation of joint with swelling, redness, pain and heat caused by 
tissue injury or disease in the joint. There are more than one hundred forms of arthritis 
and other rheumatic diseases which may cause pain, stiffness and swelling in joints 
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and other supporting structures of the body like bones, muscles, tendons and 
ligaments. Arthritis is a serious, significant and widespread chronic health problem in 
many countries. For example, in the United States, an estimated 43 million people 
suffer from arthritis or other rheumatic conditions while the number is expected to 
reach 60 million by the year 2020. Rheumatic diseases, which affect people of all 
races and ages, are the leading cause of disability among adults aged 65 and older. 
This disease affects not only the quality of life, but also poses a great financial burden 
to the government (Cai et al.，2005; Gabriel, 2001; Pincus et al.’ 1994). 
Rheumatoid arthritis (RA) is the most common type of inflammatory arthritis. It is a 
common autoimmune and systemic inflammatory disease affecting approximately 1% 
of the world population (Cai et al., 2005; Feldmann et al., 1996a; Gabriel, 2001; Joe 
et al., 1999; Kannan et al., 2005; Narendhirakannan et al., 2005; Pincus et al., 1994). 
RA is characterized by chronic, progressive, symmetrical and erosive destruction of 
peripheral joints, chronic synovitis, neovascularization and a broad spectrum of 
immune abnormalities like production of autoantibodies against immunoglobulins 
(rheumatoid factors) and cartilage proteoglycans (Joe et al., 1999; Lettesjo et al, 1998; 
Quinones et al., 2005) . Affected joints show hyperplasia of the synovia with 
increased synovial fluid volume, large cellular infiltrates of various cell types like 
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neutrophils, macrophages, fibroblasts, T cells and dendritic cells in the synovial and 
periarticular regions, high levels of proinflammatory cytokine expression and eventual 
erosion and remodeling of the cartilage and bone of the joint (Brennan et al., 1998; 
Feldmann et al., 1996b; Wipke et aL, 2001). 
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1.2 Pathogenesis of arthritis 
The etiology of RA is not known. However, evidence suggests that an infectious 
agent initiates an immune response. Whatever the etiologic agent, it most probably 
acts locally in joints by inciting an inflammatory response (Harris, 1990; McCarthy et 
al., 1998). 
This response injures small blood vessels, and mononuclear cells accumulate in the 
perivascular areas. After that, macrophages process the pathogenic materials and 
present them to lymphocytes. In inflammation, there is initial dilation of the small 
arterioles, resulting in increased blood flow, followed by slowing and then stasis of 
the blood and an increase in the permeability of the postcapillary venules, with 
exudation of fluid. The vasodilation is brought about by many mediators like 
histamine and prostaglandins. Some of these mediators like histamine are also 
responsible for the initial phase of increased vascular permeability. The fluid exudate 
contains different kinds of mediators which affect the cells in the vicinity and the 
blood vessels themselves. The exudate is carried by lymphatics to local lymph glands 
or lymphoid tissue to initiate an immune response (McCarthy et al” 1998; Rang, 
2003). 
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Some cells involved in inflammation are normally present in tissues like vascular 
endothelial cells, mast cells and tissue macrophages while some gain access to the 
inflammation site from the blood, such as platelets and leucocytes. Neutrophils are the 
first of the blood leucocytes entering the area of the inflammatory reaction. They are 
responsible for engulfing, killing and digesting microorganisms. They kill by 
generating toxic oxygen products followed by enzyme digestion. Eosinophils have 
similar capacities to neutrophils and, in addition, are armed with many potent granule 
constituents, which, when released extracellularly, can damage multicellular parasites. 
Monocytes enter the area several hours after the polymorphs. In the tissues, 
monocytes become transformed into macrophages which engulf tissue debris and 
dead cells as well as microorganisms in the inflammatory areas (Rang, 2003). 
Local antibody production ensues, and antigen-antibody complexes activate the 
complement cascade to induce further inflammation. Numerous cytokines, such as 
interleukins and tumor necrosis factors, released from the inflammatory cells 
particularly macrophages incite articular cartilage destruction. The cytokines 
stimulate the release of collagenases from the synovial cells as well as from the 
chondrocytes of the articular cartilage. This results in a breakdown of the cartilage 
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matrix. Moreover, locally released prostaglandins activate osteoclasts leading to 
osteopenia of the periarticular bone (Brennan et al., 1992; McCarthy et al” 1998). 
1.2.1 Histological changes 
All the inflammatory arthritis syndromes share similar histological features although 
the changes are most pronounced in rheumatoid arthritis (McCarthy et al., 1998). The 
changes in synovium, articular cartilage and bone are discussed in details below. 
1.2.1.1 Synovium changes 
The synovium is the main site within diaithrodial joints in which inflammation is 
initiated. It is advantageously positioned to permit this to occur. This highly vascular 
tissue is the portal through which inflammatory cells gain access to the joint. 
Moreover, the synovium has an innate complement of fixed inflammatory cells 
including mast cells, macrophages and endothelial cells, so it is subject to 
inflammatory stimuli and capable of initiating inflammatory responses (Salisbury et 
al., 1994). 
The pathologic changes in rheumatoid arthritis occur in the synovial membrane 
initially. The early changes are synovial lining cell (SLC) hyperplasia, oedema, vessel 
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proliferation, and infiltration of lymphocytes into the sublining area. SLC hyperplasia 
is due to increased migration of type A SLC to the joint from the bone marrow and by 
in situ proliferation of type B SLC. The most characteristic feature of the pathological 
changes in the synovium is an infiltrate of inflammatory cells. The principal 
inflammatory cell is the small lymphocyte. Most of these cells are CD4+ T 
lymphocytes and they are most prominent in perivascular locations. Other 
lymphocytes, particularly CD8+ T cells, are also present diffusely, but these tend to 
accumulate near the synovial membrane surface (FitzGerald et al., 1995; Haynes et 
al” 1991; Kraan et al., 1998; McCarthy et al., 1998; St. Clair et al., 2004). 
In late or advanced RA, the inflammatory processes and fibrosis are progressive. A 
mass of synovium, made up of fibroblasts, macrophages, T cells and vessels, called 
pannus develops. The synovial lining cell layer is the leading edge of pannus and 
contains collagenase, matrix metalloproteinase, and cytokines like TNF-a, IL-1 and 
IL-6 (Goldring, 2002b; Mulherin et aL, 1996; St. Clair et aL, 2004; Yanni et al, 
1994). 
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1.2.1.2 Articular cartilage degradation 
The articular cartilage changes are secondary to the inflamed synovial membrane. 
Granulation tissue originating in the synoival membrane creeps over the surface of the 
articular cartilage. Histopathological studies of joint tissues with RA have 
demonstrated that the initial area of cartilage matrix degradation occurs in areas 
contiguous with the proliferating synovial pannus (Kobayashi et al., 1975; McCarthy 
et al., 1998; St. Clair et aL, 2004; Woolley et al., 1977). 
There are two principal mechanisms by which RA synovial tissues contribute to 
cartilage loss. The first mechanism is direct and involves products, in addition to 
cytokines, produced by the RA synovium that are capable of degrading the articular 
cartilage matrix. In the region that synovial tissues adversely affect cartilage 
remodeling, there is attachment of the synovial cells, including synovial fibroblasts 
and macrophages, to the cartilage surface. Both cell types have been implicated in the 
degradation of the adjacent cartilage matrix by the release of proteinases, like matrix 
metalloproteinase, capable of digesting the cartilage matrix components (Bromley et 
al., 1984b; FitzGerald et al,, 1995; Goldring, 2003; McCarthy et al., 1998; St. Clair et 
al,, 2004). The second one is indirect and involves the effects of cytokines and other 
mediators released from the synovium that produce dysregulation of chondrocyte 
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function. These pro-inflammatory mediators act on chondrocytes to inappropriately 
degrade their pericellular matrix and suppress chondrocyte synthetic function. The 
resultant disequilibria in remodeling contribute to the rapid loss of cartilage matrix 
components characteristic of the RA joint lesion (Goldring, 2003). 
Among pro-inflammatory cytokines involved in cartilage matrix degradation, IL-1 
and TNF-a have received particular attention. These cytokines are capable of 
inducing synovial cells or chondrocytes to increase production of matrix 
metalloproteinases (MMPs), aggrecanases, and other cartilage degrading proteinases. 
The effects of TNF-a are synergistic with IL-1 in cartilage destruction. Moreover, 
they stimulate the synthesis of several additional products implicated in joint 
inflammation and cartilage matrix degradation, including prostaglandin E2, nitric 
oxide, soluble phospholipase A2 and other pro-inflammatory cytokines, such as IL-6. 
Furthermore, these cytokines contribute to the depletion of the cartilage matrix by 
decreasing the synthesis of cartilage-specific collagens and proteoglycans (Goldring, 
2003; Henderson et ai, 1989; Reginato et aL, 1993; Saklatvala, 1986). 
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1.2.L3 Bone erosions 
In maturity, the bone integrity is maintained by ongoing bone removal and 
replacement. This process involving the coupling of bone resorption to new bone 
formation is known as bone remodeling. Bone remodeling occurs in the "bone 
remodeling unit (BRU)", the structures in which bone removal by osteoclasts and its 
replacement by osteoblasts in a highly coordinated sequence. The activation of BRU 
requires signals which are likely initiated by bone lining cells. The release of matrix 
metalloproteinases is believed to prepare the bone surface for recognition by 
osteoclast precursor cells. These precursor cells differentiate into mature, 
multinucleated osteoclasts for removing mineral and matrix from bone during the 
resorptive phase. After resorption, osteoblasts subsequently differentiate into mature 
osteoblasts which then attach to regions of resorbed bone and deposit mineral and 
matrix for the new bone formation. The osteoclasts and osteoblasts are believed to 
undergo apoptosis after completing their tasks (Goldring, 2002a). 
At the end of this cycle, the amount of new bone formed should match exactly the 
amount of bone resorbed. The imbalance between bone resorption and formation 
leads to the erosive changes characteristic of the rheumatoid lesion. In fact, both 
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increased resorption as well as decreased formation occur in the rheumatoid joint 
(Gamero et aL, 1999; Goldring, 2002a). 
Recently, several lines of evidence have supported that osteoclasts are the principal 
cell type responsible for focal bone loss in RA. The interaction of the inflamed 
synovial tissues with the bone surface is speculated to result in the recruitment and 
induction of osteoclasts for digestion of the bone matrix (Bromley et al., 1984a; 
Bromley et al., 1984b; Goldring, 2003; St. Clair et aL, 2004). RA synovial tissue is a 
rich source of factors with the capacity to induce osteoclast differentiation and 
activation. These factors include IL-1, IL-6, TNF-a, macrophage colony-stimulating 
factor ( M - C S F ) and receptor activator of nuclear factor (NF)-KB ligand ( R A N K L ) . 
They can be divided into (a) those that act indirectly by up-regulating the production 
of factors from the osteoblast-lineage bone-lining cells or cells in the bone marrow 
stroma adjacent to the remodeling surfaces like IL-6 and RANKL and (b) those that 
act directly on the osteoclast or its precursors (Feldmann et aL, 1999; Gravallese et aL, 
2000a; Gravallese et aL, 2000b; St. Clair et al, 2004). 
RANKL is an essential factor regulating osteoclast differentiation and activity. It also 
plays a role in the pathogenesis of focal bone loss in RA. RANKL, which is a member 
11 
of the TNF family of ligands, exerts its actions by binding to its cognate receptor, the 
receptor activator of NF-KB ( R A N K ) . R A N K is a member of the T N F family of 
receptors and is expressed on osteoclast precursors, osteoclasts, dendritic cells and 
certain non-immune cells, notably chondrocytes. RANKL activity is regulated by a 
naturally occurring inhibitor, osteoprotegerin (OPG). OPG is a member of the 
TNF-receptor family and a soluble protein that acts as a decoy receptor by binding to 
RANKL thus preventing the normal RANKL-RANK interaction and finally 
disrupting osteoclastogenesis (Goldring, 2002a; Goldring, 2003; Gravallese et al., 
2000b; Lacey et al” 1998; Simonet et al., 1997; St. Clair et al., 2004). In 
inflammatory conditions, such as rheumatoid arthritis, RANKL is produced by the 
inflammatory cells and OPG is suppressed, resulting in osteoclast formation in the 
inflammatory tissues in the absence of osteoblasts (Findlay et al” 2005). 
TNF-a and IL-1 are cytokines that have dual sites of action on osteoclast-mediated 
bone resorption. Both factors can up-regulate RANKL expression in bone-lining and 
marrow stromal cells. Moreover, TNF-a and RANKL act in synergy to enhance 
osteoclast differentiation while IL-1 acts directly on osteoclasts to increase their 
resorbing activity. Both IL-1 and TNF-a contribute further to bone loss in RA by 
impairing bone formation via induction of osteoblast apoptosis (Goldring, 2003; 
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1.3 Western medicines for arthritis 
Rheumatoid arthritis (RA) is characterized by symmetric inflammation of synovial 
joints leading to progressive erosion of cartilage and bone. The main goals of 
treatment are to relieve pain, control inflammation and prevent irreversible joint 
destruction, so as to maintain function for essential activities of daily living and work. 
There are three major classes of drugs used in the treatment of rheumatoid arthritis: 
nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids and disease 
modifying antirheumatic drugs (DMARDs) (Langenegger et al., 1999; Stuck! et al., 
1997). 
Prior to the 1980s, the "pyramid" approach was used in the RA treatment. In this 
approach, medications from different classes and with increasing toxicity were added 
in a step-by-step manner. Aspirin and NSAIDs formed the base of the pyramid and 
were the mainstay of treatment while potent cytotoxic therapies like 
cyclophosphamide formed the peak of the pyramid. In between were DMARDs such 
as hydroxychloroquine, injectable gold salts, and methotrexate. It takes patients years 
to traverse the pyramid, and in the end, joint destruction and disability were still 
common (Doan et al., 2005). 
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Nowadays, the pyramid approach has been replaced with a "step-down" approach 
involving the institution of mono or combination DMARDs treatment at the time of 
diagnosis. It is because RA appears to be both the most aggressive and the most 
responsive to treatment early in the course of the disease and DMARDs and 
anticytokine agents control synovitis and slow or even stop the progression. A 
reduction is made in the dosage and the number of drugs taken once the patient's 
symptoms improve. Combinations of 2 or 3 DMARDs have been used in cases in 
which the response to single DMARD therapy is incomplete. The benefits of 
combination therapy can exceed those of a single agent (2002; Boers et aL, 1997; 
Doan et aL, 2005; O'Gradaigh et aL, 1999; Pincus et al., 1999). 
1.3.1 Nonsteroidal anti-inflammatory drugs (NSAIDs) 
NSAIDs block inflammation by inhibiting the synthesis of prostaglandins. All cells in 
the body produce prostaglandins in response to tissue damage. The process involves 
oxidation, cyclization and peroxidation of arachidonic acid by cyclooxygenase (COX) 
enzyme. There are two well-known types of COX enzyme, namely COX-1 and 
COX-2 (Doan et aL, 2005). COX-1 isoenzyme is constitutively expressed and is 
responsible for the synthesis of prostaglandins involved in normal physiological 
functions in platelets, the gastrointestinal tract, and the kidney while COX-2 is an 
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inducible isoform of cyclooxygenase with massive expression occurring in 
inflammation sites thereby providing substantial amounts of prostaglandins to 
contribute to the inflammation process (Firestein et aL, 2000; Garavito et al., 1999; 
Mattia et al, 2005). Therefore, it is believed that many of NSAIDs-related adverse 
effects result from COX-1 inhibition while the anti-inflammatory effect is attributable 
to inhibition of COX-2 (Langenegger et al., 1999; Mattia et al., 2005). A third 
isoform of COX, COX-3, was recently discovered. It is produced by the COX-1 gene 
and is expressed in the cerebral cortex and heart (Chaiamnuay et al., 2006; 
Chandrasekharan et al” 2002). 
NSAIDs inhibit the activity of both COX-1 and COX-2 and are used in the initial 
drug treatment of RA to reduce joint pain and swelling. Although NSAIDs are 
effective in relieving the symptoms and signs (like pain, stiffness and swelling) in the 
early stage of RA, they do not alter the course of the disease or prevent joint 
destruction (Langenegger et al., 1999; Vane, 1971). 
Although NSAIDs are well tolerated generally, they are associated with a spectrum of 
potential clinical toxicities, which varies between different compounds. None of them 
are completely safe (Langenegger et al., 1999; Singh et al” 1994). NSAIDs have a 
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propensity to produce gastrointestinal disturbances and other severe side effects, for 
example, in kidney and in cardiovascular system when used for a long time. 
Gastrointestinal toxicity is clinically the most important side effect (St. Clair et al., 
2004). COX-1 is thought to be involved in certain homeostatic functions like 
maintaining gastrointestinal mucosa integrity and conferring cytoprotection in the 
gastrointestinal tract. Its inhibition is considered the main cause of the higher 
incidence of gastrointestinal ulceration and potentially life threatening upper 
gastrointestinal perforation and bleeding associated with NSAIDs (Hemandez-Diaz et 
al., 2000; Mattia et al., 2005). 
Newer highly selective COX-2 inhibitors like celecoxib, robecoxib and valdecoxib 
inhibit only COX-2. These drugs can avoid some of the gastrointestinal side effects 
seen with nonselective inhibitors because COX-1 is required for the production of 
protective prostaglandins in the stomach (Doan et aL, 2005; Vane et al., 1998). 
However, it is found that COX-2 inhibitors are associated with an increased risk of 
cardiovascular events (Boers, 2001; Mattia et al., 2005; Mukherjee et al., 2001). This 
may be due to the imbalance between prostacyclin and thromboxane, leading to 
vasoconstriction and thrombosis (Chaiamnuay et al., 2006; Hinz et al., 2002; Mattia 
et al., 2005). Therefore, they should be considered as second or third line agents and 
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used for brief period in patients who are at low risk for cardiovascular events (Becker, 
2005). 
1.3.2 Glucocorticoids (GCs) 
Glucocorticoids are still the most effective anti-inflammatory and 
immune-suppressive substances known. They control joint inflammation in RA 
rapidly and effectively and they are powerful in relieving symptoms in RA. It is 
demonstrated that they are superior to NSAIDs in reducing pain and morning 
stiffness. 
GCs circulate in blood either in the free form or in association with cortisol-binding 
protein. After diffusion into the cell, GCs bind to a cytoplasmic specific 
phosphorylated cytosolic GC receptor (GR), which translocates to the nucleus and 
regulates the expression of multiple genes including those for interleukin-1 (IL-l), 
IL-6, nuclear factor KB, tumor necrosis factors (TNFa), lipocortin-1 and 
cyclooxygenase 2 (Bamberger et aL, 1996; Firestein et aL, 2000; Moreland et aL, 
2002). 
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The major mechanisms involved in the anti-inflammatory effects of GCs include 
down-regulation of the production of inflammatory cytokines like TNFs and IL-1 and 
a variety of proinflammatory enzymes like collagenase, increased synthesis of 
enzymes and other proteins like lipocortin 1 which inhibits phospholipase A2 thus 
blocking the arachidonic cascade and inhibition of the expression of COX-2 and 
inducible nitric oxide synthase in vascular endothelial cells (Firestein et al” 2000; 
Kurumbail et al.，1996; Moreland et al., 2002; Werb, 1978). As a result, GCs affect 
the synthesis of most major immunological and inflammatory mechanisms 
contributing to the pathogenesis of rheumatoid arthritis (Firestein et al., 2000). 
However, the known side effects, including osteoporosis, peptic ulcer disease and 
vascular disease, of long term high dose systemic administration of GCs have limited 
their usefulness as a treatment of RA. On the other hand, the efficacy is lost with low 
dosing of GCs (Doan et al., 2005; Moreland et al., 2002; Saag et al., 1994). 
The bony complications to GC therapy are insidious and perplexing and are today the 
chief concerns relating the long-term use of GCs. In RA, glucocorticoid-induced bone 
loss is superimposed on bone loss which is already increased in this disease due to 
immobilization and chronic inflammation. GCs cause osteoporosis by reducing bone 
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formation and increasing bone resorption. The major mechanisms of GC-induced 
osteoporosis include increased osteoclast function (decreased sex hormone production, 
decreased absorption of calcium and increased renal calcium loss) and direct 
inhibition of osteoblast function, as well as promotion of osteoclast survival. 
Therefore, minimizing the incidence and severity of glucocorticoid-related 
side-effects is an urgent task as glucocorticoids remain widely used (Canalis, 1996; 
Firestein et al., 2000; Lukert et aL, 1990; MacAdams et al., 1986; Manolagas et al., 
1999; Moreland et al., 2002; St. Clair et aL, 2004; Weinstein et al., 2002). 
1.3.3 Disease modifying antirheumatic drugs (DMARDs) 
Disease modifying antirheumatic drugs, which are also called slow acting 
antirheumatic drugs or disease controlling antirheumatic therapeutics, are substances 
that alter the disease course and lessen the radiological damage. Although DMARDs 
decrease disease activity and joint destruction in the short term, the beneficial long 
term effect is controversial (Edmonds et aL, 1993; Langenegger et aL, 1999). 
The most commonly used early DMARDs included sulfasalazine, parenteral gold and 
methotrexate. Sulfasalazine, which is the first DMARD that was specifically 
synthesized for the treatment of RA, is one of the first line therapies given to patients 
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with mild to moderate rheumatoid arthritis. It is formulated by linking an antibiotic, 
sulfapyridine, with anti-inflammatory agent, 5-aminosalicylic acid. Methotrexate and 
parenteral gold are the other first line drugs given to patients with moderate to severe 
disease. Methotrexate inhibits DNA synthesis by inhibiting the enzyme dihydrofolate 
reductase and the formation of reduced folates and thymidylate synthetase while 
parenteral gold has been observed to decrease cytokine release and inhibit collagenase 
action. However, the exact mechanism of action of gold salts in RA is not known 
(Doan et al., 2005; Firestein et al., 2000; Ward et al., 1983). The main problems 
associated with the long term use of DMARDs are the relevant side effects (toxicity; 
see Table 1) and the failure to reduced disease activity under a level where additional 
joint destruction is unlikely (efficacy). Therefore, combination therapy has been 
introduced in recent years. 
The rationale for using combination of DMARDs is that, by using drugs which have a 
different mechanism of action and, in particular, a different side-effect profile, it 
might be possible to have additive or synergistic effects on efficacy without an 
increase in adverse events (Cannella et al., 2003; Firestein et al., 2000; Harris, 1996). 
Methotrexate with chloroquine, methotrexate with sulfasalazine and prednisone, and 
parenteral gold with bucillamine are some examples of drug combinations. In the 
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future, efforts are needed to determine the best combinations of DMARDs, their ideal 
dosage, and the best application regimens to optimize the treatment of RA patients 
(Boers et al., 1997; Ferraz et al., 1994; Langenegger et al., 1999; Yasuda et aL, 1994). 
Table 1: side effects of some commonly used DMARDs 
Drug Side effects 
Sulfasalazine Gastrointestinal intolerance, rash and infrequent myelosuppression 
Gold Rash, stomatitis, myelosuppression, proteinuria and thrombocytopenia 
(immunomediated) 
Methotrexate Gastrointestinal symptoms, stomatitis, rash, alopecia, infrequent 
myelosuppression, hepatic toxicity and pulmonary toxicity 
1.3.4 Biological therapies 
The growth in understanding of pathological mechanisms underlying RA at the 
molecular and cellular levels has triggered an avalanche of new biological therapies 
for this disabling disease. There has been a rapid development of agents that target the 
cytokine inflammation cascade in RA (Doan et al., 2005; Langenegger et aL, 1999; 
Wallis et al., 1998). The aim of these biological agents is to antagonize 
proinflammatory cytokines such as IL-1, IL-6 and TNF-a or to stimulate or add 
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protective cytokines like IL-10. Most of these compounds are in early stages of 
experimental animal or patient research. Etancercept, which is the first available and 
approved biological compound, showed promising results in clinical controlled trials. 
The extracellular portion of TNF receptors fuse to the Fc portion of human 
immunoglobulin thus making etancercept able to bind specifically to circulating 
TNF-a or TNF-p and block their interaction with TNF receptors on the cell surface 
(Langenegger et aL, 1999; Simon et aL, 2000). 
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1.4 Traditional Chinese medicines for arthritis 
Chronic inflammatory diseases like rheumatoid arthritis (RA) remain one of the 
world's major health problems. Conventional anti-arthritic medicines like 
non-steroidal anti-inflammatory drugs (NSAIDs), disease modifying antirheumatic 
drugs (DAMRDs) and glucocorticoids are not suitable for long term use because they 
have a propensity to produce gastrointestinal disturbances and/or other severe side 
effects. Therefore, an effective anti-arthritic drug with lesser adverse effects should be 
developed. 
Nowadays, there is a growing interest internationally in the use of traditional Chinese 
medicine (TCM) (Davidson et aL, 2003; Pach et al., 2002). This is fuelled by 
dissatisfaction with traditional Western medical model, skepticism regarding adverse 
drug effects and recognition of potential benefits of TCM. TCM is perceived as a 
more natural and potentially safer alternative in the treatment of chronic illness than 
pharmaceutical drugs or surgery (Davidson et al., 2003). Thus, it has become an 
important category of complementary and alternative medicine (CAM) in Western 
countries during the past decade (Chen et al., 2007; Eskinazi, 1998). In China, TCM 
has been used to treat different kinds of diseases and symptoms such as arthritis for 
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many centuries. However, the underlying mechanisms of actions of these drugs are 
not clearly defined. 
Miao Lin (ML) is a formulation of Sen Miao San (三妙散)and Lingzhi that consists 
of Cortex Phellodendri (^tt), Atractylodisa Rhizoma (蒼Jtt)，Radix Achyranthis 
Bidentatae (牛膝)，and Ganoderma lucidum. These agents are reported to have 
anti-inflammatory and analgesic effects (Zhu, 1998), but the efficacy of ML in 
treatment of arthritic diseases is unknown. 
Figure 1： Miao Lin capsules 
1.4.1 Ganoderma lucidum 
Figure 2: Ganoderma lucidum 
Ganoderma lucidum (Fr.) Karst. (Polyporaceae) is a species of basidiomycetes 
belonging to Ganodermataceae of Aphyllophorales). It is called Lingzhi in Chinese. 
The dried fruit-body of this mushroom has a glossy exterior and a woody texture. It 
has been widely used to prevent and treat various diseases like arthritis and caner in 
many Asian countries. Its potential medicinal value, wide acceptability, and lack of 
toxicity have made it an attractive target for research (Eo et aL, 1999; Liu et aL, 2004; 
Liu et aL, 2002; Wachtel-Galor et aL, 2004; Zhu et aL, 1999). 
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1.4.1.1 Major chemical constituents 
The main chemical constituents in Ganoderma lucidum include a series of steroids, 
triteptines, amino acids, pyrrolizidine alkaloids, polysaccharides and polypeptides. Of 
these, the polysaccharides and triterpenes have been shown to possess diverse and 
potentially significant pharmacological activities. Terpenes, ganoderic acids, lucidenic 
acids and ganodermanontriol can also be isolated from this herb (Liu et al, 2004; Liu 
et al., 2002; Min et al•，1998; Zhu et al., 1999). 
1.4.1.2 Functions 
G. lucidum is found to be a potent anti-inflammatory agent as the water extract of the 
fruiting body is active orally against both croton oil-induced inflammation and 
carrageenan-induced inflammation while the ethyl acetate extract is active both orally 
and topically as an anti-inflammatory agent. The active compound is equivalent in 
anti-inflammatory activity to hydrocortisone. However, it does not show the typical 
side effects of steroids or non-steroidal anti-inflammatory drugs like aspirin 
(Stavinovah et al.’ 1991). 
G. lucidum is also found to be a sedative and analgesic agent (Liu et al，2000). Pain is 
reduced after administration of hot water soluble extract of this herb (Hijikata et al., 
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1998). Ganoderic acids A, B, G and H and compound C6 isolated from this herb have 
been demonstrated to possess antinociceptive action (Koyama et al, 1997). 
1.4.2 Cortex Phellodendri f 黃柏、 
圓纏 
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Figure 3: Cortex Phellodendri 
Cortex Phellodendri is the bark of Phellodendron chinense Schneid. or P. amurense 
Rupr. in the family of Rutaceae. The bark is peeled with care from trees of more than 
10 years old between March and June, and then dried in the sun (Zhu, 1998). 
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1.4.1.1 Major chemical constituents 
Isoquinoline alkaloids are the major chemical constituents of this herb. The major 
alkaloids include berberine, palmatine and phellodendrine. Moreover, limonoidal 
triterpenes obakulactone (limonin), obakunone and their y-hydroxybutenolides, and 
phytosterols campesterol, p-sitosterol and 7-dehydrostigmasterol were also isolated 
from the bark (Zhu, 1998). 
1.4.2.2 Traditional description 
Cortex Phellodendri has a bitter taste and a cold property, acting on the kidney, 
urinary bladder and large intestine channels. It has the functions of: 
i) clearing away heat and drying dampness, used in various damp-heat 
syndromes: dysentery, jaundice, yellow think foul leukorrhagia, swelling pain 
in the knees and feet and urinary tract infections; 
ii) purging fire and detoxicating, used in various infections on the body surface 
such as boils, sores, swelling, ulcers, eczema, canker sores, hemorrhoids, 
bums and scalds; and 
iii) clearing away heat of deficiency type, used for exuberance of fire due to Yin 
deficiency manifested by tidal fever, hectic fever with night sweat, and 
emission (Zhu, 1998). 
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1.4.2.3 Functions 
This herb exerts an antibacterial effect probably owing to berberine which can 
potentiate the phagocytic ability of macrophages. It also has anti-inflammatory effect 
by contracting the local blood vessels at inflammation site and reducing local 
inflammatory reaction (Huang, 1999; Zhu, 1998). Moreover, it was shown that 
oedema induced by 12-0-tetradecanoylphorbol-13-acetate, oxazolone and arachidonic 
acid can be inhibited significantly by the extract of this herb (Cuellar et aL, 2001). 
This herb is also a component of Qing-Luo-Yin (QLY) which is a traditional Chinese 
herbal medicine for the treatment of rheumatoid arthritis. It is found that QLY 
ameliorates the articular morphological alterations, the over expression of 
metalloproteinases (MMP)-3 mRNA and the reduced production of tissue inhibitor of 
matrix metalloproteinase (TIMP)-l in collagen-induced arthritis rats. This may be 
done by restoring the balance of MMP-3 and TIMP-1 in rheumatoid synovium (Li et 
aL, 2003). 
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1.4.3 Atractvlodisa Rhizoma f蒼 jtt� 
_ 
Figure 4: Atractylodisa Rhizoma 
Atractylodisa Rhizoma is the rhizome of Atractylodes lancea (Thunb.) DC. or A. 
chinensis (DC.) Koidz. in the family of Compositae. The rhizome is collected in 
spring and autumn, dried in the sun and then removed from fibrous roots by dashing 
(Zhu, 1998). 
1.4.3.1 Major chemical constituents 
It contains volatile oils, mainly atractylone, hinesol, P-eudesmol, atractylodin, 
P-selinene, cureument and acetylatractylodinol (Zhu, 1998). 
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1.4.3.2 Traditional description 
Atractylodisa Rhizoma is pungent and bitter in taste and warm in property, acting on 
the spleen, stomach and liver channels. It has the functions of: 
i) removing dampness and invigorating the function of the spleen, used in 
epigastric and abdominal distension, anorexia and diarrhoea; 
ii) dispelling wind-cold and removing dampness, used in oedema, particularly 
oedema of the legs with lameness, rheumatic arthralgia and cold; and 
iii) diminishing cataract and improving acuity of vision, used in eye problems 
such as external and internal oculopathy, optic atrophy and night blindness 
(Zhu, 1998). 
1.4.3.3 Functions 
The essential oil of the herb produced a sedative effect. However, overdosage may 
cause death, due to respiratory paralysis (Huang, 1999; Liu et al., 2000). 
This herb is contained in many drugs like Rikkunshi, which is shown to inhibit 
12-O-tetradecanoylphorbol-13-acetate (TPA)-induced inflammation in mice 
(Yasukawa et al., 1995). Atractylon was isolated as the active component against this 
inflammation (Zhu, 1998). 
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1.4.4 Radix Achvranthis Bidentatae 牛膝） 
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Figure 5: Radix Achyranthis Bidentatae 
Radix Achyranthis Bidentatae can be divided into Huai Niu Xi, which is the root of 
Achyranthes hidentata Blume in the family of Amaranthaceae, and Chuan Niu Xi 
{Radix Cyathulae Officinalis), which is the root of Cyathula officinalis Kuan in the 
family of Amaranthaceae. In the Chinese Pharmacopoeia, however, only the root of A. 
bidentata is designated as Niu Xi, whereas the root of C. officinalis is under a separate 
monograph Chuan Niu Xi (Xu et aL, 2002). 
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1.4.1.1 Major chemical constituents 
It contains two ecdysones; ecdysterone and inokosterone, and triterpene saponins that 
could yield oleanolic acid on hydrolysis. Several polysaccharide fractions have also 
been isolated from the root (Xu et al., 2002; Zhu, 1998). 
1.4.4.2 Traditional description 
Radix Achymnthis Bidentatae has bitter and sour tastes and a neutral property, acting 
on the liver and kidney channels. It has the functions of: 
i) replenishing the liver and kidney and strengthening the tendons and bones, 
used in soreness of the lumbar and knee joints with weakness in the legs; 
ii) eliminating blood stasis and stimulating menstrual discharge, used in 
amenorrhea, mass formation in the abdomen; and 
iii) leading the blood downward, used in hemoptysis, epistaxis, and dizziness due 
to hyperactivity of the liver (Xu et al., 2002; Zhu, 1998). 
1.4.4.3 Functions 
This herb is listed in Chinese Pharmacopoeia as a traditional Chinese medicine having 
function of strengthening the bones and muscles. It can be used to treat weakness and 
soreness of waist and knees, weakness of muscle and joint. 
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The alcoholic preparation of the herb inhibited paw oedema induced by formaldehyde 
in rats. Intraperitoneal administration of the alcoholic preparation also suppressed 
writhing reaction due to intraperitoneal injection of potassium antimony tartrate or 
acetic acid. There is a significant inhibition on ear oedema induced by croton oil, and 
foot swelling induced by formaldehyde. All these show that this herb possess 
anti-inflammatory and analgesic effects (Zhu, 1998). 
The extract of Radix Achyranthis Bidentatae is claimed to be a quite strong 
anti-inflammatory agent. The mechanism is based on boosting immunity, promoting 
phagocytosis by macrophages, dilating blood vessels, improving circulation. It is also 
found that the anti-inflammatory effect is due to the polysaccharides in this herb (Zhu, 
1998). 
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1.5 Animal models of arthritis 
Even after decades of research, the pathogenesis of arthritis is still unclear. In order to 
know more about the disease to improve diagnosis, treatment and prevention, animal 
models are very useful in experimental studies. Animal models can be used to mimic 
disease conditions without the use of human subjects. It is difficult to study the initial 
stages of arthritic disease as afflicted individuals are diagnosed normally after the 
onset of severe and chronic joint inflammation (Wipke et aL, 2001). Therefore, small 
animal models of arthritis in which the induction of disease is synchronized and 
predictable allow the contributions of specific cell types and effector molecules to the 
multiple steps of disease induction and pathogenesis to be determined (Wipke et aL, 
2001). Moreover, these models are very important in preclinical study of new drugs. 
New drugs must be tested in animal models for metabolism, toxicity, bioavailability 
and other pharmacological properties before administration to human to predicate the 
possible risks like carcinogenic and mutagenic potential, effectiveness and safety 
dosing range in human. 
Animal models can be produced by using different inducing agents including antigens, 
oil-based adjuvants and bacterial cell wall peptidoglycan-polysaccharides (Joe et aL, 
1999; Wilder et ah, 1999). The heat-killed Mycobacterium tuberculosis emulsified in 
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Freund's incomplete adjuvant is one of the most widely studied adjuvants. Arthritis 
models are commonly developed in rats and mice. This is mainly because of the cost, 
homogeneity of the genetic background, and in mice, the capacity to use genetically 
modified strains (Kannan et aL, 2005). 
1.5.1 Adjuvant-induced arthritis 
Adjuvant arthritis is recognized as a useful animal model for the study of 
pathogenesis of rheumatic diseases like rheumatoid arthritis (RA), the most common 
inflammatory arthritis (Knight et al., 1992). This model is also widely used as an 
example of chronic inflammatory disease to study the anti-inflammatory and 
anti-arthritic agents and inhibitory drugs on cartilage and bone damage (Bonnet et aL, 
1993). 
Adjuvant is an immunostimulatory agent (Holmdahl et al., 2001). The Freund's 
complete adjuvant (FCA) is a mixture of mineral oils, heat-killed mycobacteria and 
emulsifying agent while the Freund's incomplete adjuvant is formed when the 
mycobacteria is eliminated from the mixture (Freund, 1956) (Holmdahl et aL, 2001). 
FCA is proved to be an efficient enhancer of both cell-mediated and humoral immune 
responses towards the antigens with which it is emulsified (Holmdahl et aL, 2001). 
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Mycobacteria cause the formation of persistent foci of inflammation, which are often 
necrotic (granuloma), so repetitive immunizations are severely detrimental to health 
(Holmdahl et aL, 2001). 
This animal model can be induced by sub- or intradermal injection of Freund's 
complete adjuvant to certain rat strains (Chillingworth et aL, 2003b). A non-infectious 
subacute polyarthritis and inflammation develop typically 12-14 days postinjection of 
adjuvant. This manifests the swelling of articulated joints (Knight et aL, 1992). Initial 
acute inflammation of periarticular tissues and tendon sheaths can be found. The 
polymorphonuclear leucocytes exude into the synovial spaces, followed by the 
accumulation of mononuclear cells, mainly lymphocytes in the affected tissues. 
Moreover, hyperplasia of synovial lining cells and proliferation of granulation tissue 
are detected subsequently (Knight et aL, 1992). This may in turn be followed by 
subchondral bone and cartilage destruction, accompanied by rapid production of new 
bone in the adjacent periosteum (Bonnet et al., 1993; Knight et aL, 1992). After an 
early acute phase of local inflammation at the injection site, a late chronic phase 
occurs with the development of arthritis at all paws, leading to progressive joint 
destruction (Bonnet et al., 1993). Although the onset of polyarthritis is sudden, the 
disease progresses rapidly over several weeks in what appears clinically to be a 
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monophasic process and finally there is erosion and permanent damage to joints 
(Knight et al., 1992). The type of adjuvant and the strain of rat used play an important 
role in determining the severity of the lesions (Knight et aL, 1992). This model shows 
a severe but self-limiting disease and the rats recover within a few months (Holmdahl 
et aL, 2001). 
FCA-induced arthritis represents a systemic process as the disease is not joint specific 
(Butler et aL, 1992). It is associated with wide spread inflammatory infiltrates and 
granuloma formation in many organs like the spleen, liver, bone marrow, meninges, 
gastrointestinal tract, genitourinary, skin and eyes (Joe et al., 1999). The symptoms of 
swollen periarticular tissue, proliferative synovitis, subcutaneous nodules and both 
cartilage and bone destruction are similar to that found in human (Bonnet et aL, 1993). 
The adjuvant-induced model in rats also shares some features with human RA patients 
like genetic linkage, synovial CD4+ cells and T cell dependence (Goodson et al., 
2003). Between the animal model and human patients, one of the major differences is 
simply the inciting agent is known in the model even though the need for any specific 
antigen is controversial (Kannan et al., 2005). 
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It is very difficult to reproduce the adjuvant model in animals other than rats while 
cartilage protein-induced models can be established in several species like mice, rats 
and apes (Bakker et aL, 1990). However, rats offer some advantages when compared 
to mice (Holmdahl et aL, 2001). Firstly, they are more prone to develop a chronic 
relapsing disease course (Holmdahl et aL, 2001). Secondly, the inflammatory 
responses are better described like the acute phase response (Holmdahl et al.’ 2001). 
Thirdly, the size of animal is larger thus facilitating surgery and examinations 
(Holmdahl et al., 2001). Finally, rats are susceptible to both adjuvant-induced and 
cartilage protein-induced arthritis thus allowing parallel studies of the two disease 
types, often in the same strains (Holmdahl et aL, 2001). On the other hand, there are 
some disadvantages of using rats for the adjuvant model as compared to mice. For 
example, the rat model lacks embryonic stem cell-based technology, less developed 
genetic and immunological tools and higher breeding and maintenance costs 
(Holmdahl et al., 2001). 
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Table 2: Similarities and differences of adjuvant-induced arthritis compared to 
human arthritis like RA 
Animal model Similarities Differences 
Adjuvant-induced arthritis > Symmetrical joint > No rheumatoid factor 
involvement > Acute disease resolving 
> Peripheral joints affected within weeks of induction 
> Synovial hyperplasia > Rapid explosive onset of 
> Swollen periarticular tissue highly erosive polyarthritis 
> Subcutaneous nodules > Monophasic course 
> Inflammatory cell infiltration > Systemic process affecting 
> Marginal erosions gastrointestinal, genitourinary 
> Cartilage and bone tract, skin, etc. 
destruction > Axial skeleton involvement 
> Persistent joint inflammation > Inciting agent is known 
> Genetic regulation by MHC 
and non MHC genes 
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1.6 Aims of study 
Chronic inflammatory diseases like rheumatoid arthritis (RA) remain one of the 
world's major health problems. Conventional anti-arthritic medicines like 
non-steroidal anti-inflammatory drugs (NSAIDs), disease modifying antirheumatic 
drugs (DAMRDs) and glucocorticoids are not suitable for long term use because they 
have a propensity to produce gastrointestinal disturbances and/or other severe side 
effects. Therefore, an effective anti-arthritic drug with lesser adverse effects should be 
developed. 
Nowadays, there is a growing interest internationally in the use of traditional Chinese 
medicines (TCM). In China, TCM have been used to treat many different kinds of 
diseases and symptoms including arthritis for centuries. However, the scientific basis 
for the therapeutic uses of many TCM is not clearly defined. Recently, the Institute of 
Chinese Medicine of the Chinese University of Hong Kong has produced a TCM 
capsule (abbreviated as LS) that was shown to have pain relief property in RA 
patients in a 24 weeks double-blind placebo-controlled study (unpublished 
observation). The constituents of this LS capsule are Lingzhi (panoderma lucidum) 
and Sen Miao San, which is composed of Cortex Phellodendri, Atractylodisa 
Rhizoma and Radix Achyranthis Bidentatae. These ingredients are believed to have 
42 
anti-inflammatory properties; although the clinical trial showed no obvious 
anti-inflammatory benefit for the RA patients, which was suspected to be due to 
inadequate dose of LS used in the study. On the basis of these clinical findings, the 
present study aims to further elucidate the analgesic and anti-inflammatory efficacies 
of LS in an animal model of arthritis induced by injection of Freund's complete 
adjuvant (FCA) into rat knees. 
Drugs may be administered by many different routes like oral administration, 
intra-articular injection and intra-peritoneal injection, but TCM are most commonly 
taken by mouth. The oral route of drug administration will subject the drug to hepatic 
first-pass effect that may reduce its bioavailability even when the drug is well 
absorbed. Administration of drugs by injection provides a faster onset of action than 
oral administration. In clinical treatment of arthritis, both oral and intra-articular 
injection of glucocorticoids have been used. The present study will investigate and 
compare the antiarthritis efficacies of LS and dexamethasone given by oral, 
intra-articular, and intra-peritoneal routes. 
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Chapter 2 
Materials and Drugs 
Materials and solutions 
Stock drug solutions were prepared as described below. Subsequent dilutions of all 
stock solutions were made in physiological saline (0.9% NaCl) for use in experiments. 
Acid alcohol (1%) was prepared by slowly adding 1 ml concentrated hydrochloric 
acid (BDH Laboratory Supplies) to 99 ml 70% ethanol. 
Formalin buffer (10%) was prepared by dissolving 4 g NaH2P04H20 (BDH 
Laboratory Supplies) and 6.5 g NasHPCU (BDH Laboratory Supplies) in distilled 
water. 100 ml formaldehyde (Lab Scan) was added and made up to 1000 ml with 
distilled water, and stored at room temperature. 
Formic acid (10%) was prepared by adding 100 ml formic acid (Merck) to 900 ml 
distilled water, and stored at room temperature. 




Entellan (Merck) was stored at room temperature. 
Eosin yellowish solution was prepared by dissolving 1% eosin yellowish (BDH 
Laboratory Supplies, England) and 0.05% CaCl� (BDH Laboratory Supplies) in 
distilled water, and stored at room temperature. 
Ethanol (Merck) was stored at room temperature. 
Freund's complete adjuvant (FCA) (Sigma) was stored at 2 - 8 °C. 
Langzhi-Sen Miao San (LS) was provided by the Institute of Chinese Medicine at 
the Chinese University of Hong Kong. This herbal formula is composed of 35.7% 
Lingzhi and 64.3% Sen Miao San (21.4% Rhizoma atractylodis, 21.4% Cortex 
phellodendri Chinensis and 21.4% Radix achyranthis Bidentatae), and it is 
manufactured, packaged and labeled by a factory in Hong Kong based on good 
manufacturing practice standard. The crude herbs were supplied in one batch from 
reputable suppliers and were kept and stored in cool and dry place. Before the water 
extraction procedure, the crude herbs of Lingzhi, Rhizoma atractylodis. Cortex 
phellodendri Chinensis and Radix achyranthis Bidentatae were cleaned, washed and 
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cut into fragments no bigger than 6 cm in length. Rhizoma atractylodis was ground 
into powder below 100 mesh for later use. During the water extraction process, 
distilled water was added to macerate the herbs for 1 hour, and then the mixture was 
boiled at 100 for 1 hour for the first extraction. There were 3 extractions in total. 
The second extraction involved adding distilled water and boiling at 100 ""C for 1 hour 
and the third extraction involved boiling for half an hour. After extraction, the liquid 
extract was concentrated at -660 mmHg and at 60 and was spray dried to produce a 
powder extract. The dry extract powder was sieved and mixed with Rhizoma 
atractylodis powder. It was then encapsulated at 500 mg per capsule and polished and 
packaged in a clean room at 10 - 20 and 50% humidity (Bao et al.，2006; Li et al., 
2007). The powder of the LS capsule was dissolved in physiological saline for the 
present study. The suspension was used for oral administration while the supernatant 
obtained after spinning was used for intra-articular and intra-peritoneal injections. 
Lillie-Mayer Haematoxylin was prepared by boiling 50 g NH4SO4AI12H2O (BDH 
Laboratory Supplies) in 700 ml distilled water. 5 g haematoxylin monohydrate (BDH 
Laboratory Supplies) was added, heated for 2 minutes and 0.3 g sodium iodate (Sigma) 
was then added. 300 ml glycerol (BDH Laboratory Supplies) and 20 ml acetic acid 
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(Merck) were added after cooling. The solution was stored at room temperature after 
filtering. 
Paraffin Wax (Merck) was stored at room temperature and melt at 65 °C when used. 
Phosphate buffer saline (PBS) (pH 7) was prepared by dissolving 2.6 g/L 
NaHsPCUHsO (BDH Laboratory Supplies), 11.5 g/L NazHPCU (BDH Laboratory 
Supplies) and 8.5 g/L NaCl (Sigma) in distilled water，and stored at room 
temperature. 
Scott's Tap Water was prepared by dissolving 2 g potassium bicarbonate (BDH 
Laboratory Supplies) and 20 g magnesium sulphate (BDH Laboratory Supplies) in 
1000 ml distilled water. 
Thiopentone sodium (Abbott) was dissolved in physiological saline at 40 mg/ml 
upon use. 
Urethane (Sigma) was dissolved in physiological saline at 0.25 g/ml. 
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3.1 Induction of anaesthesia 
Experiments were performed on Sprague-Dawley rats (250-300 g) bred at the Chinese 
University of Hong Kong. Each cage was supplied with sufficient food and water. 
For the induction of arthritis and the measurement of knee joint size, rats were 
anaesthetized with intra-peritoneal injections of 40 mg/kg thiopentone (0.3 ml/ 300 g 
rat). For acute terminal experiments, rats were anaesthetized with intra-peritoneal 
injections of 1.8 g/kg urethane. The anaesthetized animals were constantly kept under 
observation in order to make sure that breathing was regular and slow. Sign of deep 
anaesthesia was shown by the abolition of withdrawal reflex when the hind paw of the 
rat was squeezed. 
3.2 Induction of monoarthritis 
When the rats were anaesthetized, one knee joint was injected with 0.125 ml Freund's 
complete adjuvant (FCA) containing 0.125 mg Mycobacterium tuberculosis while the 
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contralateral knee was injected with 0.125 ml (0.9%) physiological saline. The 
animals were then allowed to recover. 
3.3 Measurements of knee extension angles 
This method was described by Yu et al. (2002) with slight modifications. The 
conscious rat was restrained gently. While the thigh was fixed by holding it with the 
thumb and the second finger of one hand, the leg was extended by the fingers of the 
other hand to determine the knee extension angle at which the rat showed struggling 
behaviour. The extension angle was directly measured using the protractor by holding 
the thigh at the pivot. Each joint was measured three times at 3-min intervals and the 
average of the three was taken as the final value. 
Figure 6: Measurements of knee extension angles 
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3.4 Measurements of knee joint sizes 
The method was previously described by Lam et al. (2004). In the anaesthetized rat, a 
digital micrometer (Mitutoyo, Japan) was placed across the medial aspect of the knee 
joint holding the muscles on either side at an appropriate strength so that it touches 
but not pressing on these muscles. The reading on the micrometer was then noted. 
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Figure 7: Measurements of knee joint sizes 
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3.5 Assessment of changes in articular blood flow 
The method of laser Doppler perfusion imaging (LDI) described by Lam et al. (2004) 
was used to measure knee joint blood flow. In the anaesthetized rat, the skin over the 
knee joint was removed to expose the anteromedial aspect of the joint capsule. For the 
exposed surface, 0.1 ml saline was added every 5 minutes to prevent tissue 
dehydration. A laser Doppler perfusion imager (Moor Instruments, England), which 
was placed 28 cm above the joint, directs a helium-neon laser (633 nm) to the tissue 
and scans the joint surface in a square pattern of 2 x 2 cm in approximately 20s. Each 
joint was scanned three times with 2-rnin intervals. A colour-coded perfusion image 
was then generated and displayed on the monitor. The actual flux values at each point 
in the image were stored on disc and can be utilized for calculation of the mean flux 
value within a given area using an image processing software (Moor Instrument). The 
area selected was based on the criterion that it should include most of the articular 
tissue with minimal inclusion of the relatively less well-perfused muscle around the 
joint. 
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3.6 Assessment of morphological changes 
3.6.1 Fixation 
The method described by Lam et al. (2004) was used with slight modifications. 
Following exsanguination of the anaesthetized rats, their knee joints were dissected 
0.5 cm above and below from the patella, freed from muscles, and rinsed with 0.9% 
saline. The knee joints were then fixed in 30 ml 10% formalin with mild agitation for 
7 days. The formalin was replaced with fresh one after 4 days. 
3.6.2 Decalcification 
As tissues containing calcium cannot be sectioned after paraffin embedding, the joints 
were decalcified with 30 ml 10% formic acid with mild agitation for 8 days to remove 
the minerals in bone to soften the tissue. The calcium salts dissolve and then ionize 
during decalcification. The formic acid was replaced with fresh one after 4 days. 
Under-decalcification causes difficulty in sectioning while over-decalcification results 
in poor staining quality. In order to determine the end point of decalcification, the 
flexibility of the knee joints was tested by cutting the bone with a blade. The 
decalcified joints were trimmed to a size better suited for processing. After that, the 
joints were rinsed with running water for 4 hours to remove any excess acid and 
stored in phosphate buffer saline (PBS) for future use. 
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3.6.3 Processing 
A processing machine (Shandon, duplex Processor) was used for dehydration, 
clearing and wax infiltration of joints. In dehydration, a series of ethanol with 
increasing concentration was used to reduce the tissue shrinkage. This process started 
with a serial immersion of the joints into 70%, 85% and finally 95% ethanol for 3 
hours each, followed by three changes of 100% ethanol for 2 hours each. Clearing is 
to remove the ethanol used in dehydration and to make the tissue receptive to the 
infiltration medium. Two changes of xylene were used for 1 and 1.5 hours 
subsequently. Inadequate clearing may be followed by inadequate infiltration of tissue 
with wax while prolonged clearing results in over-hardening of tissue. After 
dehydration and clearing, joints were infiltrated with wax to hold the cells and 
intercellular structures in their proper relationship while thin sections were cut. This 
was done by three immersions of the joints into wax for 2 hours each. Agitation was 
required in each processing step. 
3.6.4 Embedding 
A hot plate (Sybron/ Thermolyne Nuova II stir plate) was used to melt the wax in the 
embedding mold. The joints were embedded with wax in the embedding mold with 
the patella facing upwards. The embedding ring was placed over the mold. The mold 
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was then placed onto the cold plate to solidify the wax and fix the joints in place in 
the mold. It was then kept at 4°C overnight. 
3.6.5 Sectioning 
The paraffin block was trimmed into a trapezium and sectioned serially to 5 fim thick 
slices by a microtome (model no.: RM2125RT, Leica). One in every 20 sections was 
selected, expanded with 20% ethanol for 10 seconds. The section was then floated on 
a water bath (Leica) at 37°C for 1 minute for further expansion and then mounted on a 
glass slide. The glass slides were kept at 37 °C overnight for drying. 
3.6.6 Staining 
Staining, which involves dew ax, hydration and dehydration, is an essential step to 
distinguish between different components of tissues. Dew ax is to remove the paraffin 
of the section. This was done by heating the glass slides in an oven (RA Lamb 
Windsor incubator) at 70°C for 20 minutes. The slides were then immersed into two 
changes of xylene for 10 minutes each. Hydration can be done by using a series of 
alcohol with decreasing concentration. The slides were put into two changes of 100% 
alcohol for 5 minutes each, followed by 95%, 85%, 70% and finally 50% alcohol for 
3 minutes each. Finally, the slides were washed by running water gently for 3 minutes. 
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Haematoxylin, which is a basic dye, binds to negatively charged tissue components. 
The slides were stained with haematoxylin for 10 minutes and then washed by 
running water for 10 minutes. The removal of non-specific staining from the sections 
can be done by dipping into 1% acid alcohol followed by washing under running 
water for 3 minutes. The immersion of Scott's tap water for 1 minute was used to 
enhance the colour of haematoxylin on the sections. After washing by running water 
for 3 minutes, the slides were then stained with eosin, which is an acid dye binding to 
positively charged tissue components, for 8 minutes. The removal of excess eosin was 
done by dipping the slides into water and subsequently 70% alcohol. Finally, 
dehydration started with a series of alcohol with increasing concentration. This can be 
done by immersion of slides into 70% alcohol for 1 minute, 85% and 95% alcohol for 
3 minutes each followed by three changes of 100% alcohol for 5 minutes each. After 
the immersion of slides into two changes of xylene for 5 minutes each to remove 
alcohol, coverslips were mounted onto the slides with the use of entellan. 
3.6.7 Scoring 
Each histological score represents an average score of three sections taken from the 
middle vertical axis of each joint that showed clearly all the structures of the joint. 
Scoring was carried out by two blinded observers, focusing especially on 
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polymorphonuclear cell infiltration, synovial tissue proliferation, and cartilage erosion 
of the joint. The severity of the lesions was classified into four grades: 0 = no change; 
1 = mild change; 2 = moderate change; and 3 = marked change. 
3.7 Statistical analysis 
Extension angles were expressed as means 土 S.E.M. of angles measured in degrees 
while knee joint sizes were expressed as means 土 S.E.M. of sizes measured in 
millimeters. Results from blood flow studies were expressed as the means (flux values) 
± S.E.M. of selected areas of the LDI images. Histological changes were expressed as 
means 土 S.E.M. of an arbitrary scale of severity from 0 to 3. Mean values were 
compared by paired or unpaired Student's Mest as appropriate. The significance of 
difference between treatment effects was analysed by repeated measures two-factor 
analysis of variance (ANOVA), followed by the Bonferroni post hoc test for 
comparisons of means. P values < 0.05 were considered to be statistically significant. 
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Chapter 4 
Adjuvant-induced Monoarthritic Rats 
4.1 Adjuvant-induced monoarthritic rats (1 week) 
4.1.1 Method 
After anaesthetizing Sprague-Dawley rats (250-300 g) with intra-peritoneal injections 
of 40 mg/kg thiopentone, one knee joint was injected with 0.125 ml Freund's 
complete adjuvant (FCA) containing 0.125 mg Mycobacterium tuberculosis while the 
contralateral knee was injected with 0.125 ml (0.9%) physiological saline at day 0. 
The body weight, knee extension angle that provoked struggling behaviour, and knee 
joint size of the rats were measured on day 0 prior to induction of arthritis, and on 
days 1, 2，3, 4 and 7 after induction of arthritis, while knee joint blood flow was 
measured on day 7; these correspond to indexes of algesia, oedema and hyperaemia, 
respectively. At the end of the experiment, the knee joints were excised and processed 
for histological examination (for details, see previous Methods Section on page 47). 
Histological scores on the extent of cell infiltration, tissue proliferation, and erosions 
of cartilage and bone in the knee joints were used as additional indexes of the arthritis 
condition at the end of the experiment. 
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4.1.2 Results 
4.1.2.1 Body weight 
As shown in Figure 4.1.1，there was a significant increase in body weight on day 7 
compared with the weight prior to induction of arthritis on day 0 (n=8; P<0.01; 
one-factor ANOVA). 
4.1.2.2 Knee joint sizes 
Unilateral intra-articular injection of FCA into the synovial cavities of rat knees 
produced significant swelling when compared with their contralateral saline-injected 
knees (n=8;尸<0.001; two factor ANOVA). The knee joint sizes of FCA-injected 
knees were significantly greater than those of the saline-injected knees from day 1 to 
day 7 (PcO.OOl; Bonferroni post-hoc test). These results are shown in Figure 4.1.2. 
4.1.2.3 Knee extension angles 
There was significant difference in knee extension angles that provoked struggling 
behaviour in FCA-injected knees and their contralateral saline-injected knees (n=8; 
P<0.001; two factor ANOVA). FCA-injected knees required to be extended 
significantly less than their contralateral saline-injected knees to produce struggling 
59 
behaviour (indicating reduced pain threshold) from day 1 to day 7 (P<0.001; 
Bonferroni post-hoc test). These results are shown in Figure 4.1.3. 
4.1.2.4 Knee joint blood flow 
There was significant difference in knee joint blood flow between FCA-injected knees 
and their contralateral saline-injected knees. The blood flow in the contralateral 
saline-injected knees is significantly lowered than that in the FCA-injected knees (n=8; 
P<O.Or’ paired r-test). These results are shown in Figure 4.1.4. 
4.1.2.5 Histological evaluation 
4.1.2.5.1 Cell infiltration 
As shown in Figure 4.1.5 and Figure 4.1.6，unilateral intra-articular injection of FCA 
produced marked immune cell infiltration in the synovial tissue of rat knee joints 
when compared with their contralateral saline-injected knees. The immune cells were 
closely and densely packed in the synovial tissue of FCA-injected knees (n=8; 
PcO.OOl; paired Mest). 
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4.1.2.5.2 Synovial tissue proliferation 
Compared with their contralateral saline-injected knees, rat knees injected with FCA 
showed significant tissue proliferation 1 (n=8; F<0.001; paired r-test). These results 
are shown in Figure 4.1.5 and Figure 4.1.6. 
4.1.2.5.3 Cartilage degradation 
There was significant cartilage degradation in FCA-injected knees compared with 
their contralateral saline-injected knees (n=8; P<0.001; paired r-test). Unlike the 
FCA-injected knees, the cartilage surface in their contralateral saline-injected knees 
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Figure 4.1.1 
Effects of unilateral intra-articular injection of Freund's complete adjuvant (FCA) on 
body weight of SD rats. There was a significant increase in body weight at day 7 
compared with the weight prior to induction of arthritis on day 0 (n=8; **P<0.01; 
one-factor ANOVA). Data are shown as means 土 S.E.M. (shown by vertical bars) of 
weight expressed in gram. 
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Figure 4.1.2 
Effects of unilateral intra-articular injection of Freund's complete adjuvant (FCA) on 
knee joint sizes of SD rats. There was significant difference in knee joint sizes 
between FCA-injected knees and their contralateral saline-injected knees (n=8; 
***P<0.001; two factor ANOVA). Subsequent analysis by Bonferroni post-hoc test 
showed that FCA-injected knees were significantly larger than their contralateral 
saline-injected knees from day 1 to day 7 (###/^<0.001). Data are shown as means 土 
S.E.M. (shown by vertical bars) of knee joint sizes expressed in percentage change. 
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Figure 4.1.3 
Effects of unilateral intra-articular injection of Freund's complete adjuvant (FCA) on 
knee extension angles that provoked struggling behaviour in SD rats. There was 
significant difference in knee extension angles that provoked struggling behaviour in 
FCA-injected knees and their contralateral saline-injected knees (n=8; ***P<0.001; 
two factor ANOVA). Subsequent analysis by Bonferroni post-hoc test showed that 
FCA-injected knees had reduced pain threshold compared with their contralateral 
saline-injected knees from day 1 to day 7 (###P<0.001). Data are shown as means 土 
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Effects of unilateral intra-articular injection of Freund's complete adjuvant (FCA) on 
knee joint blood flow of SD rats. There was significant increase in knee joint blood 
flow in FCA-injected knees compared with their contralateral saline-injected knees 
(n=8; **P<0.01; paired r-test). Data are shown as means 士 S.E.M. (shown by vertical 
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Figure 4.1.5 
Effects of unilateral intra-articular injection of Freund's complete adjuvant (FCA) on 
(A) cell infiltration, (B) synovial tissue proliferation and (C) cartilage erosion in 
synovial tissues of rat knee joints. 0.125 ml FCA or saline was injected into synovial 
cavities of the rat knees 7 days before histological examination. All these three 
arthritic parameters in FCA-injected knees were significant greater than their 
contralateral saline-injected knees (n=8; ***P<0.001; paired r-test). 
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Figure 4.1.6 
Micrographs of rat knee joints. Immune cell infiltration (I), synovial tissue 
proliferation (P), and cartilage erosion (E) were identified in FCA-injected knees but 
not in the contralateral saline-injected knees (n=8; ***/><0.001; paired /-test). Fe, T, M, 
C and F represent femur, tibia, meniscus, cartilage and fat cells respectively. 
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4.2 Adjuvant-induced monoarthritic rats (2 weeks) 
4.2.1 Method 
After anaesthetizing Sprague-Dawley rats (250-300 g) with intra-peritoneal injections 
of 40 mg/kg thiopentone, one knee joint was injected with 0.125 ml Freund's 
complete adjuvant (FCA) containing 0.125 mg Mycobacterium tuberculosis while the 
contralateral knee was injected with 0.125 ml (0.9%) physiological saline at day 0. 
The body weight, knee extension angle that provoke struggling behaviour, and knee 
joint size of the rats were measured on day 0 prior to induction of arthritis, and on 
days 1, 2, 3，4, 7，9, 11，and 14 after induction of arthritis, while knee joint blood flow 
was measured on day 14; these correspond to indexes of algesia, oedema and 
hyperaemia, respectively. At the end of the experiment, the knee joints were excised 
and processed for histological examination (for details, see previous Methods Section 
on page 47). Histological scores on the extent of cell infiltration, tissue proliferation, 
and erosions of cartilage and bone in the knee joints were used as additional indexes 
of the arthritis condition. 
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4.2.2 Results 
4.2.2.1 Body weight 
As shown in Figure 4.2.1，compared with the body weight at prior to induction of 
arthritis on day 0, there was a significant decrease in body weight on days 2 and 4 
(n=8; P<0.05 for both; one-factor ANOVA). On the other hand, the body weight 
increased significantly on days 11 and 14 (P<0.05 and PcO.OOl; one-factor ANOVA). 
4.2.2.2 Knee joint sizes 
Unilateral intra-articular injection of FCA into synovial cavities of rat knees produced 
significant swelling when compared with their contralateral saline-injected knees (n=8; 
P<0.001; two factor ANOVA). Knee joint sizes of FCA-injected knees were 
significantly greater than those of the saline-injected knees from day 1 to day 14 
(P<0.001; Bonferroni post-hoc test). These results are shown in Figure 4.2.2. 
4.2.2.3 Knee extension angles 
There was significant difference in knee extension angles that provoked struggling 
behaviour in FCA-injected knees and their contralateral saline-injected knees (n=8; 
P<0.001; two factor ANOVA). FCA-injected knees required to be extended 
significantly less than their contralateral saline-injected knees to produce struggling 
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behaviour from day 1 to day 9 (P<0.001; Bonferroni post-hoc test). These results are 
shown in Figure 4.2.3. 
4.2.2.4 Knee joint blood flow 
There was significant difference in knee joint blood flow between FCA-injected knees 
and their contralateral saline-injected knees. The blood flow in the contralateral 
saline-injected knees was significantly lowered than that in the FCA-injected knees 
(n=8; P<0.05; paired (-test). These results are shown in Figure 4.2.4. 
4.2.2.5 Histological evaluation 
4.2.2.5.1 Cell infiltration 
As shown in Figure 4.2.5 and Figure 4.2.6, unilateral intra-articular injection of FCA 
produced marked immune cell infiltration in synovial tissues of rat knee joints when 
compared with that of their contralateral saline-injected knees. The immune cells were 
closely and densely packed in synovial tissue of the FCA-injected knees (n=8; 
P<0.001; paired Mest). 
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4.2.2.5.2 Synovial tissue proliferation 
Compared with their contralateral saline-injected knees, rat knees injected with FCA 
showed significant tissue proliferation (n=8; PcO.OOl; paired Mest). These results are 
shown in Figure 4.2.5 and Figure 4.2.6. 
4.2.2.5.3 Cartilage degradation 
There was significant cartilage erosion in FCA-injected knees compared their 
contralateral saline-injected knees (n=8; PcO.OOl; paired Mest). Unlike the 
FCA-injected knees, cartilage surface in their contralateral saline-injected knees was 
very smooth and was showed no sign of erosion. These results are shown in Figure 
4.2.5 and Figure 4.2.6. 
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Figure 4.2.1 
Effects of unilateral intra-articular injection of Freund's complete adjuvant (FCA) on 
body weight of SD rats. Compared with the body weight prior to induction of arthritis 
on day 0, there was a significant decrease in body weight on days 2 and 4 (n=8; 
*P<0.05; one-factor ANOVA). On the other hand, the body weight increased 
significantly on days 11 and 14 (*尸<0.05，***P<0.001; one-factor ANOVA). Data are 
shown as means 土 S.EM, (shown by vertical bars) of weight expressed in gram. 
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Figure 4.2.2 
Effects of u n i l a t e r a l intra-articular injection of Freund's complete adjuvant (FCA) on 
knee joint sizes of SD rats. There was significant difference in knee joint sizes 
between FCA-injected knees and their contralateral saline-injected knees (n=8; 
***P<0.001; two factor ANOVA). Subsequent analysis by Bonferroni post-hoc test 
showed that FCA-injected knees were significantly larger than their contralateral 
saline-injected knees from day 1 to day 14 (##*P<0.001). Data are shown as means 土 
S.E.M. (shown by vertical bars) of knee joint sizes expressed in percentage change. 
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Figure 4.2.3 
Effects of unilateral intra-articular injection of Freund's complete adjuvant (FCA) on 
knee extension angles that provoked struggling behaviour in SD rats. There was 
significant difference in knee extension angles that provoked struggling behaviour in 
FCA-injected knees and their contralateral saline-injected knees (n=8; ***P<0.001; 
two factor ANOVA). Subsequent analysis by Bonferroni post-hoc test showed that 
FCA-injected knees had reduced pain threshold compared with their contralateral 
saline-injected knees from day 1 to day 9 (#拥/^<0.001). Data are shown as means 土 
S.E.M. (shown by vertical bars) of changes in extension angle expressed in 
percentage change. 
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Effects of unilateral intra-articular injection of Freund's complete adjuvant (FCA) on 
knee joint blood flow of SD rats. There was significant increase in knee joint blood 
flow in FCA-injected knees compared with their contralateral saline-injected knees 
(n=8; *P<0.05; paired /-test). Data are shown as means 土 S.E.M. (shown by vertical 
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Figure 4.2.5 
Effects of unilateral intra-articular injection of Freund's complete adjuvant (FCA) on 
(A) cell infiltration, (B) synovial tissue proliferation and (C) cartilage erosion in 
synovial tissues of rat knee joints. 0.125 ml FCA or saline was injected into synovial 
cavities of the rat knees 14 days before histological examination. All these three 
arthritic parameters in FCA-injected knees was significant greater than their 
contralateral saline-injected knees (n=8; ***P<0.001; paired Mest). 
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Figure 4.2.6 
Micrographs of rat knee joints. Immune cell infiltration (I), synovial tissue 
proliferation (P), and cartilage erosion (E) were identified in FCA-injected knees but 
not in the contralateral saline-injected knees (n=8; ***P<O.OOl; paired t-test). Fe, T, M, 
C and F represent femur, tibia, meniscus, cartilage and fat cells respectively. 
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4.3 Discussions 
Animal models can be used to mimic disease conditions without the use of human 
subjects. Therefore, they are very useful for experimental studies to enhance our 
understanding of the disease processes, and to improve diagnosis, treatment and 
prevention of the disease. Moreover, animal models are very important in preclinical 
studies of new drugs to predicate their possible benefits and risks before human 
administration. 
Sub- or intradermal injection of Freund's complete adjuvant (FCA) has been widely 
used to induce a rheumatoid arthritis-like condition in rats. However, this 
adjuvant-induced polyarthritic model has many disadvantages as it is often 
accompanied with widespread systemic disease and severe discomfort in the animal. 
Therefore, it has been modified to give a less severe arthritis by injection of FCA into 
or around the joint, which results in a localized monoarthritis. This monoarthritis 
model enables study of the arthritis condition without many complicating factors like 
poor animal mobility, altered weight gain and systemic diseases (Chillingworth et al., 
2003a; Lam et al., 2004). 
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The above monoarthritis model was adopted in the present study. Sprague-Dawley 
(SD) rats were used in the present study as they are cheap and readily available, and 
they are one of the most commonly used strains of rats in laboratories all over the 
world (Cai et al.’ 2006). It was found that unilateral intra-articular injection of 0.125 
ml FCA containing 0.125 mg Mycobacterium tuberculosis produced discrete 
monoarthritis in the rat knee joint that showed joint swelling, reduced pain threshold, 
hyperaemia, immune cell infiltration, synovial tissue proliferation and cartilage 
erosion over a time course of 7 to 14 days following the induction of arthritis. These 
changes were found only in the ipsilateral knee thus confirming the status of a discrete 
monoarthritis. This agrees with a previous report that suggest the spread of arthritis in 
a rat arthritis model was dependent on the dose of adjuvant used (Donaldson et aL, 
1993). 
Moreover, the results were readily reproducible; all rats showed a monoarthritis at the 
site of FCA injection. This suggests that unilateral intra-articular injection of FCA can 
successfully produce monoarthritic model in SD rats. Some research groups showed 
unsatisfactory incidence of adjuvant-induced arthritis in SD rats (Banik et al., 2002), 
which may be due to differences in the experimental protocols; arthritis was induced 
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by intra-dermal injection of FCA into the rat tail instead of intra-articular injection of 
FCA into the rat knee joint. 
Rheumatoid arthritis is characterized by erosive destruction of peripheral joints. 
Affected joints show hyperplasia of the synovia with infiltration of inflammatory cells. 
Destructive inflammation of the synovial membrane progressively invades and 
destroys the extracellular matrices of cartilage and bone of joints over the course of 
the disease (Cai et al., 2006; McGonagle et al., 1999). All these human pathological 
characteristics can be observed in the present monoarthritis rat model. Histological 
sections of knee joints of the present model showed extensive cellular infiltration, 
tissue proliferation with erosive pannus formation, and marked destruction of 
cartilage. This model, sharing several clinical and pathological features with human, 
provides a powerful platform to mimic the human disease condition for testing 
potential new therapeutic agents for the disease. 
Although the present rat model of adjuvant-induced monoarthritis resembles many 
features in human RA patients, it lacks the chronicity of the human disease as the rats 
were found to show improvement of symptoms two weeks after the induction of 
arthritis. This is not a surprising finding as Staines and Wooley (1994) have shown 
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that adjuvant-induced arthritic model resolved within weeks of induction (Staines et 
aL, 1994). Therefore, this model is better suited for assessing drugs with fast on set of 
actions. 
Pain is an important symptom in arthritis. The knee extension angle that provoked 
struggling behaviour was measured as an arthritic pain index in this study. After the 
induction of arthritis, FCA-injected knees increased in size and required to be 
extended significantly less to produce struggling behaviour, indicating a reduction in 
pain threshold. This result is consistent with a previous study that demonstrated 
reduction of the knee extension angle after the induction of arthritis, and it was 
co-varied over time and the degree of oedema in adjuvant-induced arthritic model (Yu 
et al, 2002). 
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Chapter 5 
Effects of intra-articular injection of LS in 
adjuvant-induced monoarthritic rats 
5.1 Method 
Sprague-Dawley rats (250-300 g) were anaesthetized with intra-peritoneal injections 
of 40 mg/kg thiopentone on day 0, and then on each rat, one knee was injected with 
0.125 ml Freund's complete adjuvant (FCA) containing 0.125 mg Mycobacterium 
tuberculosis while the contralateral knee was injected with 0.125 ml (0.9%) 
physiological saline. 
For the first group of rats, dexamethasone was administered by intra-articular 
injection one day after induction of arthritis (1.7 |ig/kg/day). In another two groups of 
rats, intra-articular injection of dexamethasone (1.7 |j.g/kg/day) or LS (8 mg/kg/day) 
was given on day 1 and day 2 after induction of arthritis. 
The body weight, knee extension angle that provoked struggling behaviour, and knee 
joint size of the rats were measured on day 0 prior to induction of arthritis, and on 
days 1, 2, 3, 4 and 7 after induction of arthritis, while knee joint blood flow was 
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measured on day 7; these correspond to indexes of algesia, oedema and hyperaemia, 
respectively. At the end of the experiment, the knee joints were excised and processed 
for histological examination (for details, see previous Methods Section on page 47). 
Histological scores on the extent of cell infiltration, tissue proliferation, and erosions 
of cartilage and bone in the knee joints were used as additional indexes of the arthritis 
condition. 
5.2 Results 
5.2.1 Body weight 
There was no significant difference in body weight of rats with single intra-articular 
injection of dexamethasone (n=8; P>0.05; one factor ANOVA). On the other hand, 
the body weight of rats injected with two doses of dexamethasone decreased 
significantly on day 3 and day 4 (n=8; PcO.Ol; one factor ANOVA). Similarly, the 
body weight of rats injected with two doses of LS decreased significantly on days 2, 3 
and 4 (n=8; P<0.05, P<0.01; one factor ANOVA). These results are shown in Figures 
5.1-5.3. 
5.2.2 Knee joint size 
Single intra-articular injection of dexamethasone reduced swelling of FCA-injected 
knees compared with FCA-injected knees of rats that had not been treated with 
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dexamethasone (n=8; P<0.001; two factor ANOVA). The suppression was significant 
from day 2 onwards (P<0.05, P<0.001; Bonferroni post-hoc tests), but these knee 
joints were still more swollen than their corresponding contralateral saline-injected 
knees from day 1 onwards (P<0.001; two factor ANOVA; PcO.OOl; Bonferroni 
post-hoc tests). The knee joint sizes between contralateral saline-injected knees of rats 
with and without dexamethasone treatment were not significantly different from each 
other (P>0.05; two factor ANOVA). These results are shown in Figure 5.4. 
Similarly, the swelling of FCA-injected knees was reduced after two intra-articular 
injections of dexamethasone compared with FCA-injected knees of rats that had not 
been treated with dexamethasone (n=8; P<0.001; two factor ANOVA). The 
suppression was significant on days 2, 3 and 4 (P<0.001; Bonferroni post-hoc tests), 
but these knee joints were still more swollen than their corresponding contralateral 
saline-injected knees from day 1 onwards (尸<0.001; two factor ANOVA; P<0.001; 
Bonferroni post-hoc tests). There was no significant difference in knee joint sizes 
between contralateral saline-injected knees of rats with and without dexamethasone 
treatment (P>0.05; two factor ANOVA). These results are shown in Figure 5.5. 
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On the other hand, the swelling of FCA-injected knees increased, especially on days 2 
and 3, after two intra-articular injections of LS when compared with FCA-injected 
knees of rats that had not been injected with LS (n=8; P<0.001; two factor ANOVA; 
P<0.01; Bonferroni post-hoc tests). After LS administration, FCA-injected knees 
remained significantly larger than their contralateral saline-injected knees (P<0.001; 
two factor ANOVA; PcO.OOl; Bonferroni post-hoc tests). There was no significant 
difference in knee joint sizes between contralateral saline-injected knees of rats with 
and without LS treatment (P>0.05; two factor ANOVA). These results are shown in 
Figure 5.6. 
5.2.3 Knee extension angle 
The FCA-injected knees of rats with single intra-articular injection of dexamethasone 
required to be extended much greater than the FCA-injected knees of rats without 
dexamethasone treatment in order to provoke struggling behaviour (n=8; PcO.OOl; 
two factor ANOVA). On day 2; the day after dexamethasone injection, the 
FCA-injected knees and contralateral saline-injected knees of dexamethasone-treated 
rats showed no different in extension angles that provoked struggling behaviour 
(尸〉0.05; Bonferroni post-hoc tests). Extension angles that provoked struggling 
behaviour in contralateral saline-injected knees of rats with and without 
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dexamethasone treatment were not significantly different (P>0.05; two factor 
ANOVA), but they required to be extended much greater than their respective 
FCA-injected knees to produce struggling behaviour (***P<0.001; two factor 
ANOVA). These results are shown in Figure 5.7. 
Similarly, two intra-articular injections of dexamethasone alleviated pain in the 
FCA-injected knees particularly on days 2, 3 and 4, which had extension angles that 
provoked struggling behaviour close to those of their corresponding contralateral 
saline-injected knees (P>0.05; Bonferroni post-hoc tests), but they were much greater 
than those in FCA-injected knees of rats without dexamethasone treatment (n=8; 
P<0.001; two factor ANOVA). There was no significant difference in extension 
angles that provoked struggling behaviour in contralateral saline-injected knees of rats 
with and without dexamethasone treatment (P>0.05; two factor ANOVA), but they 
were much greater than their respective FCA-injected knees (PcO.OOl; two factor 
ANOVA). These results are shown in Figure 5.8. 
Knee extension angles that provoked struggling behaviour were not significantly 
different in FCA-injected knees with and without LS treatment (n=8; P>0.05; two 
factor ANOVA). There was also no significant difference between extension angles 
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that provoked struggling behaviour in the contralateral saline-injected knees of these 
two groups of rats (P>0.05; two factor ANOVA), but they were much greater than 
their respective FCA-injected knees from day 1 onwards (P<0.001; two factor 
ANOVA; P<0.001; Bonferroni post-hoc tests). These results are shown in Figure 5.9. 
5.2.4 Knee joint blood flow 
As shown in Figure 5.10, single or two intra-articular injections of dexamethasone did 
not significant affect blood flow of FCA-injected knees (n=8;尸〉0.05; unpaired r-test). 
Similarly, two intra-articular injections of LS did not alter the hyperaemic response in 
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Figure 5.1 
Effects of single intra-articular injection of dexamethasone on body weight in 
adjuvant-induced monoarthritic rats. Dexamethasone (1.7 ^ig/kg/day) was injected 
into the rat knee joints one day after induction of monoarthritis. There was no 
significant difference in body weight throughout the 8 days of experiment (n=8; 
P>0.05; one factor ANOVA). Data are shown as means 土 S.E.M. (shown by vertical 
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Figure 5.2 
Effects of two intra-articular injections of dexamethasone on body weight in 
adjuvant-induced monoarthritic rats. Dexamethasone (1.7 |j,g/kg/day) was injected 
into the rat knee joints on days 1 and 2 after induction of monoarthritis. There was 
significant reduction in body weight on days 3 and 4 (n=8; **P<0.01; one factor 
ANOVA). Data are shown as means 土 S.E.M. (shown by vertical bars) of weight 
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Figure 5.3 
Effects of two intra-articular injections of LS on body weight in adjuvant-induced 
monoarthritic rats. LS (8 mg/kg/day) was injected into the rat knee joints on days 1 
and 2 after induction of monoarthritis. There was significant reduction in body weight 
on days 2, 3 and 4 (n=8; *P<0.05, **P<0.01; one factor ANOVA). Data are shown as 
means 土 S.E.M. (shown by vertical bars) of weight expressed in gram. 
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Figure 5.4 
Effects of single intra-articular injection of dexamethasone on knee joint sizes of 
adjuvant-induced monoarthritic rats. Dexamethasone (1.7 j^g/kg/day) was injected 
into the rat knee joints one day after induction of monoarthritis. There was significant 
difference in knee joint sizes between FCA-injected knees of rats with and without 
dexamethasone treatment; the former group had reduced swelling ( n=8; ***尸<0.001; 
two factor ANOVA), but were still more swollen than their contralateral 
saline-injected knees (***P<0.001; two factor ANOVA). There was no significant 
difference in knee joint sizes between contralateral saline-injected knees of rats with 
and without dexamethasone treatment (P>0.05; two factor ANOVA). Bonferroni 
post-hoc tests: #P<0.05,醒PcO.OOl (FCA-injected knees of rats with dexamethasone 
treatment vs without); +++尸<0.001 (FCA-injected knees of rats with dexamethasone 
treatment vs their contralateral saline-injected knees). Data are shown as means 土 
S.E.M. (shown by vertical bars) of knee joint sizes expressed in percentage change. 
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Figure 5.5 
Effects of two intra-articular injections of dexamethasone on knee joint sizes of 
adjuvant-induced monoarthritic rats. Dexamethasone (1.7 jig/kg/day) was injected 
into the rat knee joints on days 1 and 2 after induction of monoarthritis. There was 
significant difference in knee joint sizes between FCA-injected knees of rats with and 
without dexamethasone treatment; the former group had reduced swelling (n=8; 
***P<0.001; two factor ANOVA), but were still more swollen than their contralateral 
saline-injected knees (***P<0.001; two factor ANOVA). There was no significant 
difference in knee joint sizes between contralateral saline-injected knees of rats with 
and without dexamethasone treatment (P>0.05; two factor ANOVA). Bonferroni 
post-hoc tests:蔣#尸<0.001 (FCA-injected knees of rats with dexamethasone treatment 
vs without); +++尸<0.001 (FCA-injected knees of rats with dexamethasone treatment vs 
their contralateral saline-injected knees). Data are shown as means 土 S.E.M. (shown 
by vertical bars) of knee joint sizes expressed in percentage change. 
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Figure 5.6 
Effects of two intra-articular injections of LS on knee joint sizes of adjuvant-induced 
monoarthritic rats. LS (8 mg/kg/day) was injected into the rat knee joints on days 1 
and 2 after induction of monoarthritis. There was significant difference in knee joint 
sizes between FCA-injected knees of rats with and without LS treatment; the former 
group had increased swelling (n=8; **P<0.001; two factor ANOVA), and were more 
swollen than their contralateral saline-injected knees (***P<0.001; two factor 
ANOVA). There was no significant difference in knee joint sizes between 
contralateral saline-injected knees of rats with and without LS treatment (P>0.05; two 
factor ANOVA). Bonferroni post-hoc tests: ##P<0.01 (FCA-injected knees of rats 
with LS treatment vs without); +++P<0.001 (FCA-injected knees of rats with LS 
treatment vs their contralateral saline-injected knees). Data are shown as means ± 
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Figure 5.7 
Effects of single intra-articular injection of dexamethasone on knee extension angles 
that provoked struggling behaviour in adjuvant-induced monoarthritic rats. 
Dexamethasone (1.7 }xg/kg/day) was injected into the rat knee joints one day after 
induction of monoarthritis. There was significant difference in knee extension angles 
that provoked struggling behaviour in FCA-injected knees of rats with and without 
dexamethasone treatment (n=8; ***户<0.001; two factor ANOVA). Extension angles 
of their contralateral saline-injected knees were not significantly different ( P � 0 . 0 5 ; 
two factor ANOVA), but they required to be extended much greater than their 
respective FCA-injected knees to produce struggling behaviour (***P<0.001; two 
factor ANOVA). Bonferroni post-hoc tests: ###P<0.001 (FCA-injected knees of rats 
with dexamethasone treatment vs without); +++P<0.001 (FCA-injected knees of rats 
with dexamethasone treatment vs their contralateral saline-injected knees). Data are 
shown as means 土 S.E.M. (shown by vertical bars) of changes in extension angle 
expressed in percentage change. 
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Figure 5.8 
Effects of two intra-articular injections of dexamethasone on knee extension angles 
that provoked struggling behaviour in adjuvant-induced monoarthritic rats. 
Dexamethasone (1.7 }ig/kg/day) was injected into the rat knee joints on days 1 and 2 
after induction of monoarthritis. There was significant difference in knee extension 
angles that provoked struggling behaviour in FCA-injected knees of rats with and 
without dexamethasone treatment (n=8; ***P<0.001; two factor ANOVA). Extension 
angles of their contralateral saline-injected knees were not significantly different 
(P>0.05; two factor ANOVA), but they required to be extended much greater than 
their respective FCA-injected knees to produce struggling behaviour (***P<0.001; 
two factor ANOVA). Bonferroni post-hoc tests: ^ V < 0 . 0 0 1 (FCA-injected knees of 
rats with dexamethasone treatment vs without); +++P<0.001 (FCA-injected knees of 
rats with dexamethasone treatment vs their contralateral saline-injected knees). Data 
are shown as means 土 S.E.M. (shown by vertical bars) of changes in extension angle 
expressed in percentage change. 
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Figure 5.9 
Effects of two intra-articular injections of LS on knee extension angles that provoked 
struggling behaviour in adjuvant-induced monoarthritic rats. LS (8 mg/kg/day) was 
injected into the rat knee joints on days 1 and 2 after induction of monoarthritis. There 
was no significant difference in knee extension angles that provoked struggling 
behaviour in FCA-injected knees of rats with and without LS treatment (n=8; P>0.05; 
two factor ANOVA). Extension angles of their contralateral saline-injected knees 
were also not significantly different (P�0.05; two factor ANOVA), but they required 
to be extended much greater than their respective FCA-injected knees to produce 
struggling behaviour (***P<0.001; two factor ANOVA). Bonferroni post-hoc tests: 
+++P<0.001 (FCA-injected knees of rats with LS treatment vs their contralateral 
saline-injected knees). Data are shown as means 土 S.E.M. (shown by vertical bars) of 
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Figure 5.10 
Effects of intra-articular injection of dexamethasone or LS on knee joint blood flow in 
adjuvant-induced monoarthritic rats. Blood flow of FCA-injected knees in rats treated 
with single or two injections of dexamethasone (1.7 |ig/kg/day) showed a trend of 
decrease but they were not significantly different to that of FCA-injected knees of rats 
that had not been treated with dexamethasone (n=8; P>0.05; unpaired r-test). 
Similarly, blood flow of FCA-injected knees in rats treated with two injections of LS 
(8 mg/kg/day) showed a decrease but it was not significantly different to that of 
FCA-injected knees of rats that had not been treated with LS (n=8; P>0.05; unpaired 
r-test). Data are shown 
as means ± S.E.M. (shown by vertical bars) of changes in 
blood flow expressed in flux. 
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5.3 Discussions 
Glucocorticoids such as dexamethasone have potent immunosuppressive effects and 
have been widely used as anti-inflammatory agents for chronic inflammatory diseases 
like RA (Cuzzocrea et al., 2005; Han et al., 2001; Nagashima et al., 2000). They 
control joint inflammation in RA rapidly and effectively and they are powerful in 
relieving symptoms of RA. 
Administration of drugs by injection usually produces a faster on set of action than by 
the oral route. Injection of drugs at their local site of action also minimizes systemic 
side effects. Glucocorticoids were the first class of drugs administered by local 
intra-articular injection to treat arthritis (Furtado et aL, 2005). Such route of 
administration of glucocorticoids has demonstrated an excellent safety record over 
many years and was described by the American College of Rheumatology (ACR) as 
"safe and effective when administered by an experienced physician" (2002; 
Schumacher et aL, 2005). Therefore, it is still widely used nowadays (af Klint et al, 
2005; Schumacher et al., 2005). However, there are also some drawbacks associated 
with intra-articular injection. The risks are mainly related to the discomfort of the 
procedure; localized pain post-injection and flushing. Septic arthritis, which is the 
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most feared side effect occurred in nearly 1 in 10000 injections, can be solved by 
careful aseptic techniques (Hunter et al., 1999; Schumacher et aL, 2005). 
Glucocorticoids such as dexamethasone has been shown to down-regulate the 
expression of several inflammatory genes, including those encoding cytokines such as 
TNF-a, IL-l and IL-6 (Caldenhoven et al., 1995; Cuzzocrea et al., 2005; Han et aL, 
2001). Dexamethasone is a common anti-inflammatory drug used for treatment of RA 
for a long time (Cuzzocrea et al.’ 2005). Animal studies by Tsao et aL, also showed 
that dexamethasone at the dose of 1 mg/kg po was effective in suppressing swelling 
and improving the histological changes found in adjuvant-induced arthritic rats (Tsao 
et al., 1997). Therefore, dexamethasone was used as a positive control in the present 
study. Intra-articular injection gives local effect at knee joint so a low dose of 
dexamethasone (1.7 |ig/kg/day) was used in the present study. 
In the present study, single intra-articular injection of dexamethasone into the rat knee 
joints was investigated. Dexamethasone was administered to the rats by intra-articular 
injection one day after induction of arthritis. This produced significant reduction of 
the joint swelling and pain in the FCA-injected knees, but the effect was very 
short-lasting as it was subsided after 1 day. This is not unexpected since previous 
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studies have shown that long term therapy with glucocorticoids was necessary to 
control the symptoms of RA and other rheumatic conditions (Cuzzocrea et al., 2005). 
Therefore, the effect of intra-articular injection of dexamethasone for two consecutive 
days after the induction of arthritis was tested to examine whether its anti-arthritis 
action can be extended. 
The present findings showed that double intra-articular injections of dexamethasone 
dramatically reduced inflammatory swelling and pain in the FCA-injected knees, and 
the duration of these effects were extended to 3 days instead of 1 day of the single 
injection of dexamethasone. Following this protocol, contents of the LS capsules were 
dissolved in saline (0.05 g/ml) and administered to the rats by intra-articular injection 
for two consecutive days after induction of arthritis. Intra-articular injection gives 
local effect at knee joint so a low dose of LS was investigated in the present study. LS 
did not relieve any arthritic symptoms including joint swelling and pain in the 
FCA-injected knees. In fact, LS produced a slight increase in joint swelling instead of 
the expected suppression. The double injections of LS also caused dramatic weight 
lost in the animals. This suggests that intra-articular injections of two doses of LS 
might be too toxic (probably due to its acidic nature of pH 4.27) and these produced 
further damage of the inflamed joints leading to more severe inflammation. Therefore, 
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intra-articular injection of LS is inappropriate for treatment of arthritis, and other 
routes of administration should be considered. In fact, frequent intra-articular 
injections of drugs is usually not well-tolerated by patients, and most clinicians 
recommend a gap of at least 3 months between intra-articular injections of 
corticosteroids in the treatment of arthritic diseases (Balch et al., 1977; Hunter et al., 
1999; Rozental et al., 2000; Schumacher et al., 2005). 
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Chapter 6 
Effects of oral administration of LS in 
adiuvant-induced monoarthritic rats 
6.1 Oral administration of LS for 6 days after induction of arthritis 
6,1.1 Method 
Sprague-Dawley rats (250-300 g) were anaesthetized with intra-peritoneal injections 
of 40 mg/kg thiopentone on day 0，and then on each rat, one knee joint was injected 
with 0.125 ml Freund's complete adjuvant (FCA) containing 0.125 mg 
Mycobacterium tuberculosis while the contralateral knee was injected with 0.125 ml 
(0.9%) physiological saline. 
For the first group of rats, dexamethasone (1 mg/kg/day) was administered daily by 
oral route for 6 days after induction of arthritis. For the second and third group of rats, 
LS (0.5 g/kg/day or 1 g/kg/day) was given by the same protocol. 
The body weight, knee extension angle that provoked struggling behaviour, and knee 
joint size of the rats were measured on day 0 prior to induction of arthritis, and on 
days 1，2，3, 4 and 7 after induction of arthritis, while knee joint blood flow was 
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measured on day 7; these correspond to indexes of algesia, oedema and hyperaemia, 
respectively. At the end of the experiment, the knee joints were excised and processed 
for histological examination (for details, see previous Methods Section on page 47). 
Histological scores on the extent of cell infiltration, tissue proliferation, and erosions 
of cartilage and bone in the knee joints were used as additional indexes of the arthritis 
condition. 
6.1.2 Results 
6.1.2.1 Body weight 
There was no significant difference in body weight of rats treated with oral LS 
administrations (0.5 g/kg/day and 1 g/kg/day) throughout the 7 days duration of the 
experiment (尸〉0.05 for both; one factor ANOVA). On the other hand, the body 
weight decreased significantly from day 2 onwards after dexamethasone treatment 
(P<0.001; one factor ANOVA). These results are shown in Figure 6.1.1 - 6.1.3 
6.1.2.2 Knee joint size 
The swelling of FCA-injected knees in rats after oral administration of 
dexamethasone were reduced compared with those without dexamethasone 
administration (n=9 for both;尸<0.001; two factor ANOVA). The suppressions were 
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significant from day 2 onwards (PcO.OOl; Bonferroni post-hoc tests), but they were 
still more swollen than their contralateral saline-injected knees from day 1 onwards 
(尸<0.001; two factor ANOVA; P<0.01, P<0.001; Bonferroni post-hoc tests). The 
knee joint sizes between contralateral saline-injected knees of rats with and without 
dexamethasone treatment were not significantly different from each other (P>0.05; 
two factor ANOVA). These results are shown in Figure 6.1.4. 
The swelling of FCA-injected knees in rats after oral administration of LS (0.5 
g/kg/day) were similar to those without LS treatment (n=8 for both; P>0.05; two 
factor ANOVA). There was no significant difference between the sizes of the 
contralateral saline-injected knees of these two groups of rats (P>0.05; two factor 
ANOVA), but they were smaller than their respective FCA-injected knees from day 1 
onwards (P<0.001; two factor ANOVA; PcO.OOl; Bonferroni post-hoc tests). These 
results are shown in Figure 6.1.5. 
Similarly, high dose of LS (1 g/kg/day) did not suppress the swelling of FCA-injected 
knees compared with those without LS treatment (n=8-9 for both; P�0.05; two factor 
ANOVA). There was no significant difference between the sizes of the contralateral 
saline-injected knees of these two groups of rats (P>0.05; two factor ANOVA), but 
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they were smaller than their respective FCA-injected knees from day 1 onwards 
(PcO.OOl; two factor ANOVA; P<0.001; Bonferroni post-hoc tests). These results are 
shown in Figure 6.1.6. 
6.1.2.3 Knee extension angle 
The FCA-injected knees in rats treated with dexamethasone required to be extended 
much greater than those without dexamethasone treatment to produce struggling 
behaviour (n=9; P<0.001; two factor ANOVA); extension angles in the 
dexamethasone treated group were larger from day 2 onwards (PcO.OOl; Bonferroni 
post-hoc tests) and they were not significantly different to those of their contralateral 
saline-injected knees from day 4 onwards. Extension angles of the contralateral 
saline-injected knees of these two groups of animals were not significantly different 
(P>0.05; two factor ANOVA), but they required to be extended much greater than 
their respective FCA-injected knees to produced struggling behaviour (P<0.001 for 
both; two factor ANOVA). These results are shown in Figure 6.1.7. 
Knee extension angles that provoked struggling behaviour were not significantly 
different in FCA-injected knees of rats with and without LS treatment (n=8; P>0.05; 
two factor ANOVA). There was also no significant difference between extension 
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angles of their contralateral saline-injected knees (P>0.05; two factor ANOVA), but 
they required to be extended much greater than their respective FCA-injected knees to 
produce struggling behaviour from day 1 onwards (P<0.001 for both; two factor 
ANOVA; P<0.001; Bonferroni post-hoc tests). These results are shown in Figure 
6.1.8. 
Similarly, high dose LS did not alleviate pain in the FCA-injected knees compared to 
those without LS treatment (n=8-9; P>0.05; two factor ANOVA). Extension angles of 
the contralateral saline-injected knees of these two groups of rats were also not 
significantly different (P>0.05; two factor ANOVA)，but they required to be extended 
much greater than their respective FCA-injected knees to produce struggling 
behaviour from day 1 onwards (P<0.001 for both; two factor ANOVA; PcO.OOl; 
Bonferroni post-hoc tests). These results are shown in Figure 6.1.9. 
6.1.2.4 Knee joint blood flow 
As shown in Figure 6.1.10，there was a significant reduction in knee joint blood flow 
in the FCA-injected knees of rats treated with dexamethasone compared to that 
without dexamethasone treatment (n=8-9;尸<0.001; unpaired r-test). However, both 
low (0.5 g/kg/day) and high doses (1 g/kg/day) of LS did not reduce hyperaemia in 
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the FCA-injected knees compared to rats without LS treatment (n=8; P>0.05 for both; 
unpaired r-test). 
6.1.2.5 Histological evaluation 
6.1.2.5.1 Cell infiltration 
As shown in Figure 6.1.12, cell infiltration levels in FCA-injected knees of rats 
treated with dexamethasone, and low or high dose of LS were significantly reduced 
compared with control rats that had not received oral treatment (n=7-9; P<0.05 -
PcO.Ol; paired Mest). The contralateral saline-injected knees of rats treated with 
dexamethasone and low dose LS showed reduced cell infiltration compared with 
control (P<0.001 and P>0.05, respectively; paired r-test). These results were shown in 
the micrographs in Figure 6.1.11 and Figure 6.1.12. 
6.1.2.5.2 Synovial tissue proliferation 
FCA-injected knees of rats treated with dexamethasone showed reduced synovial 
tissue proliferation compared with control rats that had not received oral treatment 
(n=8; P<0.05; paired r-test). However, LS did not reduce synovial tissue proliferation 
in FCA-injected knees compared with control (n=7-9; P>0.05; paired r-test). There 
was no significant difference in synovial tissue proliferation levels in contralateral 
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saline-injected knees of rats treated with dexamethasone or low dose LS (P>0.05 for 
both; paired r-test) compared to control, but rats treated with high dose LS showed a 
higher level of synovial tissue proliferation (P<0.01; paired /-test). These results are 
shown in the micrographs in Figure 6.1.13 and Figure 6.1.14. 
6.1.2.5.3 Cartilage degradation 
The level of cartilage degradation in FCA-injected knees of rats treated with LS (both 
0.5 g/kg/day and 1 g/kg/day) was significantly lower than that in control rats that had 
not received oral treatment (n=7-9; P<0.01, P<0.001; paired r-test), but 
dexamethasone treatment did not produce a significant reduction (n=8;尸〉0.05; paired 
Mest). Contralateral saline-injected knees of all treatment groups showed no cartilage 
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Figure 6.1.1 
Effects of 6 days oral administration of dexamethasone (Dex) on body weight of 
adjuvant-induced monoarthritic rats. Dex (1 mg/kg/day) was administered to the rats 6 
days after induction of monoarthritis on day 0. There was a significant reduction in 
body weight from day 2 onwards after Dex treatment (***P<0.001; one-factor 
ANOVA). Data are shown as means 土 S.E.M (shown by vertical bars) of weight 
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Figure 6.1.2 
Effects of 6 days oral administration of LS on body weight of adjuvant-induced 
monoarthritic rats. LS (0.5 g/kg/day) was administered to the rats for 6 days after 
induction of monoarthritis on day 0. There was no significant difference in body 
weight of rats throughout the course of the experiment (n=8; P>0.05; one factor 
ANOVA). Data are shown as means 土 S.E.M. (shown by vertical bars) of weight 
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Figure 6.1.3 
Effects of 6 days oral administration of LS on body weight of adjuvant-induced 
monoarthritic rats. LS (1 g/kg/day) was administered to the rats for 6 days after 
induction of monoarthritis on day 0. There was no significant difference in body 
weight of rats with LS treatment throughout the course of the experiment (n=9; 
P>0.05; one factor ANOVA). Data are shown as means 土 S.E.M. (shown by vertical 
bars) of weight expressed in gram. 
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Figure 6.1.4 
Effects of 6 days oral administration of Dex on knee joint sizes of adjuvant-induced 
monoarthritic rats. Dex (1 mg/kg/day) was administered to the rats for 6 days after 
induction of monoarthritis on day 0. There was significant difference in knee joint 
sizes between FCA-injected knees of rats with and without Dex treatment; the former 
had reduced swelling (n=9 for both; ***P<0.001; two factor ANOVA), but were still 
more swollen than their contralateral saline-injected knees (***P<0.001; two factor 
ANOVA). There was no significant difference in knee joint sizes between 
contralateral saline-injected knees of rats with and without Dex treatment (n=9; 
P>0.05; two factor ANOVA). Bonferroni post-hoc tests: #^P<0.001 (FCA-injected 
knees with LS treatment vs without); ++P<0.01，+++/^<0.001 (FCA-injected knees with 
LS treatment vs their contralateral saline-injected knees). Data are shown as means 土 
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Figure 6.1.5 
Effects of 6 days oral administration of LS on knee joint sizes of adjuvant-induced 
monoarthritic rats. LS (0.5 g/kg/day) was administered to the rats for 6 days after 
induction of monoarthritis on day 0. There was no significant difference in knee joint 
sizes between FCA-injected knees with and without LS treatment (n=8 for both; 
P>0.05; two factor ANOVA). Knee joint sizes of their contralateral saline-injected 
knees were also not significantly different (P�0.05; two factor ANOVA), but they 
were smaller than their respective FCA-injected knees (***P<0.001; two factor 
ANOVA). Bonferroni post-hoc tests: ""^PcO.OOl (FCA-injected knees with LS 
treatment vs their contralateral saline-injected knees). Data are shown as means 土 
S.E.M. (shown by vertical bars) of knee joint sizes expressed in percentage change. 
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Figure 6.1.6 
Effects of 6 days oral administration of LS on knee joint sizes of adjuvant-induced 
monoarthritic rats. LS (1 g/kg/day) was administered to the rats for 6 days after 
induction of monoarthritis on day 0. There was no significant difference in knee joint 
sizes between FCA-injected knees with and without LS treatment (n=8-9 for both; 
P>0.05; two factor ANOVA). Knee joint sizes of their contralateral saline-injected 
knees were also not significantly different (P>0.05; two factor ANOVA), but they are 
smaller than their respective FCA-injected knees (***P<0.001; two factor ANOVA). 
Bonferroni post-hoc tests: + 杆PcO.OOl (FCA-injected knees with LS treatment vs their 
contralateral saline-injected knees). Data are shown as means 士 S.E.M. (shown by 
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Figure 6.1.7 
Effects of 6 days oral administration of Dex on knee extension angles that provoked 
struggling behaviour in adjuvant-induced monoarthritic rats. Dex (1 mg/kg/day) was 
administered to the rats for 6 days after induction of monoarthritis on day 0. There 
was significant difference in knee extension angles that provoked struggling 
behaviour in FCA-injected knees with and without Dex treatment (n=9; ***P<0.001; 
two factor ANOVA). Extension angles of their contralateral saline-injected knees 
were not significantly different (尸〉0.05; two factor ANOVA), but they required to be 
extended much greater than their respective FCA-injected knees to produced 
struggling behaviour (***P<0.001 for both; two factor ANOVA). Bonferroni post-hoc 
tests: —PcO.OOl (FCA-injected knees with Dex treatment vs without); ++/^<0.01, 
+++P<0.001 (FCA-injected knees with Dex treatment vs their contralateral 
saline-injected knees); (contralateral saline-injected knees with Dex 
treatment vs without). Data are shown as means 土 S.E.M. (shown by vertical bars) of 
changes in extension angle expressed in percentage change. 
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Figure 6.1.8 
Effects of 6 days oral administration of LS on knee extension angles that provoked 
struggling behaviour in adjuvant-induced monoarthritic rats. LS (0.5 g/kg/day) was 
administered to the rats for 6 days after induction of monoarthritis on day 0. There 
was no significant difference in knee extension angles that provoked struggling 
behaviour in FCA-injected knees with and without LS treatment (n=8; P>0.05; two 
factor ANOVA). Extension angles of their contralateral saline-injected knees were 
also not significantly different (P>0.05; two factor ANOVA), but they required to be 
extended much greater than their respective FCA-injected knees to produce struggling 
behaviour (•••PcO.OOl for both; two factor ANOVA). Bonferroni post-hoc tests: 
+++/^<0.001 (FCA-injected knees with LS treatment vs their contralateral 
saline-injected knees). Data are shown as means 土 S.E.M. (shown by vertical bars) of 
changes in extension angle expressed in percentage change. 
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Figure 6.1.9 
Effects of 6 days oral administration of LS on knee extension angles that provoked 
struggling behaviour in adjuvant-induced monoarthritic rats. LS (1 g/kg/day) was 
administered to the rats for 6 days after induction of monoarthritis on day 0. There 
was no significant difference in knee extension angles that provoked struggling 
behaviour in FCA-injected knees with and without LS treatment (n=8-9; P�0 .05 ; two 
factor ANOVA). Extension angles of their contralateral saline-injected knees were 
also not significantly different (尸〉0.05; two factor ANOVA), but they required to be 
extended much greater than their respective FCA-injected knees to produce struggling 
behaviour (***P<0.001 for both; two factor ANOVA). Bonferroni post-hoc tests: 
+++P<0.001 (FCA-injected knees vs their contralateral saline-injected knees with LS 
treatment). Data are shown as means 土 S.E.M. (shown by vertical bars) of changes in 
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Figure 6.1.10 
Effects of 6 days oral administration of Dex or LS on knee joint blood flow of 
adjuvant-induced monoarthritic rats. Dex (1 mg/kg/day) or LS (0.5 g/kg/day or 1 
g/kg/day) were administered to the rats for 6 days after induction of monoarthritis. 
There was a significant reduction in blood flow in the FCA-injected knees after Dex 
administration (n=8-9; ***P<0.001; unpaired r-test). There was no significant 
difference in knee joint blood flow between FCA-injected knees with and without LS 
treatments (0.5 g/kg/day and 1 g/kg/day) (n=8-9; P>0.05 for both; unpaired Mest). 
Data are shown as means 土 S.E.M. (shown by vertical bars) of changes in blood flow 
expressed in flux. 
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(A) FCA-injected (test) knees (B) Saline-injected (contralateral) knees 
(a) FCA (a) Saline 
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Cell infiltration in synovial tissues of FCA-injected test knees (A) and 
saline-injected contralateral knees (B) of rats without oral treatment (a), and with 6 
days oral administration of 1 mg/kg/day Dex (b), 0.5 g/kg/day LS (c), andl g/kg/day 
LS (d). Magnification = 5X. 
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Effects of 6 days oral administration of Dex or LS on cell infiltration in synovial 
tissues of FCA-injected test knees (A) and saline-injected contralateral knees (B) of 
rats. Oral administrations of drugs were given daily. Compared with control rats that 
had not received oral treatment, there was a significant decrease in cell infiltration 
level in FCA-injected knees of rats treated with Dex, and low or high dose LS (n=7-9; 
*P<0.05 - **P<0.01; paired r-test). Cell infiltration levels in contralateral 
saline-injected knees of rats treated with Dex and low dose LS were significantly 
reduced compared with control (n=7-8; •**尸<0.001 and *P<0.05, respectively; paired 
r-test). 
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Figure 6.2.17 
Synovial tissue proliferation of FCA-injected test knees (A) and saline-injected 
contralateral knees (B) of rats without oral treatment (a), and with 6 days oral 
administration of 1 mg/kg/day Dex (b), 0.5 g/kg/day LS (c), and 1 g/kg/day LS (d). 
Magnification = 2.5X. 
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Figure 6.2.17 
Effects of 6 days oral administration of Dex or LS on synovial tissue proliferation of 
FCA-injected test knees (A) and saline-injected contralateral knees (B) of rats. Oral 
administrations of drugs were given daily. Compared with control rats that had not 
received oral treatment, synovial tissue proliferation was significantly reduced in 
FCA-injected knees of rats treated with Dex (n=8; *P<0.05; paired r-test). The level of 
synovial tissue proliferation was significantly higher in contralateral saline-injected 
knees of rats treated with high dose LS compared with control (n=8-9; P>0.01; paired 
r-test). 
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Cartilage degradation of FCA-injected test knees (A) and saline-injected contralateral 
knees (B) of rats without oral treatment (a), and with 6 days oral administration of 1 
mg/kg/day Dex (b), 0.5 g/kg/day LS (c), and 1 g/kg/day LS (d). Magnification = 5X. 
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Effects of 6 days oral administration of Dex or LS on cartilage degradation of 
FCA-injected test knees (A) and saline-injected contralateral knees (B) of rats. Oral 
administrations of drugs were given daily. Compared with control rats that had not 
received oral treatment, there was a significant reduction in cartilage degradation in 
FCA-injected knees of rats treated with low and high doses of LS (n=7-9; **P<0.01 
and ***P<0.001, respectively; paired r-test). There was no sign of cartilage 
degradation in contralateral saline-injected knees of all treatment groups. 
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6.2 Oral administration of LS for 7 days before and 7 days after induction of 
arthritis 
6.2.1 Method 
Sprague-Dawley rats (250-300 g) were anaesthetized with intra-peritoneal injections 
of 40 mg/kg thiopentone on day 0，and then on each rat, one knee joint was injected 
with 0.125 ml Freund's complete adjuvant (FCA) containing 0.125 mg 
Mycobacterium tuberculosis while the contralateral knee was injected with 0.125 ml 
(0.9%) physiological saline. 
For the first and the second groups of rats, dexamethasone (0.01 mg/kg/day or 0.1 
mg/kg/day) was administered daily by the oral route for 7 days before and 7 days after 
induction of arthritis. For the third and forth group of rats, LS (0.5 g/kg/day) and 
saline (1 ml/kg/day) were given by the same protocol respectively. 
The body weight, knee extension angle that provoked struggling behaviour, and knee 
joint size of the rats were measured on day 0 prior to induction of arthritis, and on 
days 1, 2, 3，4 and 7 after induction of arthritis, while knee joint blood flow was 
measured on day 7; these correspond to indexes of algesia, oedema and hyperaemia, 
respectively. At the end of the experiment, the knee joints were excised and processed 
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for histological examination (for details, see previous Methods Section on page 47). 
Histological scores on the extent of cell infiltration, tissue proliferation, and erosions 
of cartilage and bone in the knee joints were used as additional indexes of the arthritis 
condition. 
6.2.2 Results 
6.2.2.1 Body weight 
There was a significant reduction in body weight of rats after oral administration of 
high dose dexamethasone (0.1 mg/kg/day) especially on days 4, 5 and 6 (P<0.05, 
P<0.01; one factor ANOVA). On the other hand, the body weight increased 
significantly in the vehicle group that received oral saline administration especially on 
days 0’ 3, 5, 6 and 7 (P<0.05, P<0.01, PcO.OOl; one factor ANOVA). There was no 
significant change on body weight for the groups that received low dose 
dexamethasone (0.01 mg/kg/day) or LS (0.5 g/kg/day) treatment. These results are 
shown in Figures 6.2.1 - 6.2.4. 
6.2.2.2 Knee joint size 
The swelling of FCA-injected knees in rats treated with oral administration of low 
dose dexamethasone (0.01 mg/kg/day) were reduced compared with those without 
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dexamethasone administration (n=9 for both;尸<0.001; two factor ANOVA). The 
reductions were significant on days 1，3, and 4 (P<0.05 - P<0.001; Bonferroni 
post-hoc tests), but they were still more swollen than their contralateral saline-injected 
knees from day 1 onwards (户<0.01; two factor ANOVA; P<0.01 -尸<0.001; 
Bonferroni post-hoc tests). The knee joint sizes between contralateral saline-injected 
knees of these two groups of rats were not significantly different to each other 
(P>0.05; two factor ANOVA). These results are shown in Figure 6.2.5. 
Swelling of FCA-injected knees in rats treated with high dose dexamethasone (0.1 
mg/kg/day) were significantly reduced compared to those without dexamethasone 
treatment (n=5-8; P<0.05; two factor ANOVA), especially from day 1 to day 4 
(P<0.05,尸<0.001; Bonferroni post-hoc tests), but they were still more swollen than 
their contralateral saline-injected knees (P<0.001; two factor ANOVA). Sizes of 
contralateral saline-injected knees of this two groups of rats were not significantly 
different to each other (P>0.05; two factor ANOVA). These results are shown in 
Figure 6.2.6. 
Similarly, LS treatment (0.5 g/kg/day) suppressed swelling of the FCA-injected knees 
compared to those without LS treatment (n=9 for both; P<0.05; two factor ANOVA), 
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especially on day 1 and day 7 (P<0.05, P<0.001; Bonferroni post-hoc tests). There 
was no significant difference between sizes of contralateral saline-injected knees of 
these two groups of rats (P>0.05; two factor ANOVA), but they were smaller than 
their respective contralateral saline-injected knees from day 1 onwards (P<0.001; two 
factor ANOVA; P<0.001; Bonferroni post-hoc tests). These results are shown in 
Figure 6.2.7. 
The swelling of FCA-injected knees in rats that received oral administration of saline 
were similar to those without saline administration (n=5-8 for both; P>0.05; two 
factor ANOVA). There was also no significant difference between sizes of their 
contralateral saline-injected knees (P>0.05; two factor ANOVA), which were smaller 
than their respective FCA-injected knees from day 1 onwards (P<0.001; two factor 
ANOVA; P<0.001; Bonferroni post-hoc tests). These results are shown in Figure 
6.2.8. 
6.2.2.3 Knee extension angle 
The FCA-injected knees of rats treated with low dose dexamethasone (0.01 
mg/kg/day) required to be extended much greater than those without dexamethasone 
treatment to produce struggling behaviour (n=4-8; P<0.01; two factor ANOVA); 
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extension angles of the dexamethasone treated group were larger from day 2 onwards 
(P<0.05, P<0.01, PcO.OOl; Bonferroni post-hoc tests) and they were not significantly 
different from those of their contralateral saline-injected knees on day 3 and day 7 
(尸<0.05; PcO.Ol; Bonferroni post-hoc tests). Extension angles of contralateral 
saline-injected knees of these two groups of rats were not significantly different 
(P>0.05; two factor ANOVA), but they required to be extended much greater than 
their respective FCA-injected knees to produce struggling behaviour (尸〉0.05; two 
factor ANOVA). These results are shown in Figure 6.2.9. 
Similarly, treatment with high dose dexamethasone (0.1 mg/kg/day) alleviated pain in 
the FCA-injected knees as they required to be extended greater to produce struggling 
behaviour compared to those without dexamethasone treatment from day 1 onwards 
(n=5-8; PcO.OOl; two factor ANOVA; PcO.Ol，P<0.001; Bonferroni post-hoc tests). 
Extension angles of the contralateral saline-injected knees of these two groups of rats 
were not significantly different (P>0.05; two factor ANOVA), but they required to be 
extended much greater than their respective FCA-injected knees to produce struggling 
behaviour from day 1 onwards (P<0.001 for both; two factor ANOVA; P<0.05, 
尸<0.01; Bonferroni post-hoc tests). These results are shown in Figure 6.2.10. 
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Knee extension angles that provoked struggling behaviour in FCA-injected knees of 
rats with and without LS treatment (0.5 g/kg/day) were not significantly different 
(n=9;尸〉0.05; two factor ANOVA). There was also no significant difference between 
extension angles of their contralateral saline-injected knees (户〉0.05; two factor 
ANOVA), but they required to be extended much greater than their respective 
FCA-injected knees to produce struggling behaviour from day 1 onwards (PcO.OOl 
for both; two factor ANOVA;尸<0.01，P<0.001; Bonferroni post-hoc tests). These 
results are shown in Figure 6.2.11. 
Similarly, knee extension angles that provoked struggling behaviour in FCA-injected 
knees of rats with and without oral saline administration were not significantly 
different (n=5-8; P>0.05; two factor ANOVA). Extension angles of their contralateral 
saline-injected knees were also not significantly different (P>0.05; two factor 
ANOVA), but they required to be extended much greater than their respective 
FCA-injected knees to produce struggling behaviour from day 1 onwards (P<0.001 
for both; two factor ANOVA; P<0.01, PcO.OOl; Bonferroni post-hoc tests). These 
results are shown in Figure 6.2.12. 
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6.2.2.4 Knee joint blood flow 
As shown in figure 6.2.13, a significant reduction in blood flow was found in 
FCA-injected knees of rats that had received high dose oral dexamethasone (0.1 
mg/kg/day) (n=5-8; P<0.05; unpaired r-test) but not in those that had received low 
dose oral dexamethasone (0.01 mg/kg/day) (n=4-8; P>0.05; unpaired /-test). Oral 
administration of LS (0.5 g/kg/day) reduced hyperaemia in the inflamed knees (n=9; 
PcO.Ol; unpaired Mest), but oral administration of saline had no effect (n=5-8; 
P>0.05; unpaired r-test). 
6.2.2.5 Histological evaluation 
6.2.2.5.1 Cell infiltration 
As shown in the micrographs in Figure 6.2.14，the level of cell infiltration in 
FCA-injected knees of rats treated with oral dexamethasone (n=4-8;尸<0.001; paired 
r-test) and LS (n=8-9;尸<0.001; paired r-test) was greatly reduced compared with that 
of the control rats that had not received oral treatment. 
The contralateral saline-injected knees of rats treated with dexamethasone showed 
lower cell infiltration level than those in the control rats (P<0.01, P<0.001; paired 
r-test). However, there was no significant difference in cell infiltration level between 
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contralateral saline-injected knees of rats with LS treatment and the control group 
(P>0.05; paired Mest). These results were shown in the micrographs in Figure 6.2.14 
and Figure 6.2.15. 
6.2.2.5.2 Synovial tissue proliferation 
Synovial tissue proliferation in FCA-injected knees of rats treated with oral 
dexamethasone (0.1 mg/kg/day) (n=4-8; P<0.05; paired r-test) was significantly 
reduced compared with that of the control rats that had not received oral treatment. 
However, LS treatment had no effect on synovial tissue proliferation compared with 
the control group (n=8-9; P>0.05; paired r-test). No significant difference was found 
in contralateral saline-injected knees of rats treated with dexamethasone or LS 
compared with the control group (P>0.05 for both; paired r-test). These results were 
shown in the micrographs in Figure 6.2.16 and Figure 6.2.17. 
6.2.2.5.3 Cartilage degradation 
FCA-injected knees of rats treated with oral dexamethasone or LS showed reduced 
cartilage degradation compared with the control rats that had not received oral 
treatment (n=4-9; P<0.05 and P<0.001, respectively; paired Mest). There was 
negligible cartilage degradation in contralateral saline-injected knees of all treatment 
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groups (P>0.05 for all; paired r-test). These results are shown in the micrographs in 
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Figure 6.2.1 
Effects of 14 days oral administration of dexamethasone (Dex) on body weight of 
adjuvant-induced monoarthritic rats. Dex (0.01 mg/kg/day) was administered to the 
rats 7 days before and 7 days after induction of monoarthritis on day 0. There was no 
significant difference in body weight throughout the duration of the experiment. Data 
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Figure 6.2.2 
Effects of 14 days oral administration of Dex on body weight of adjuvant-induced 
monoarthritic rats. Dex (0.1 mg/kg/day) was administered to the rats 7 days before 
and 7 days after induction of monoarthritis on day 0. A significant reduction in body 
weight was found on days 4，5 and 6 (*P<0.05, **P<0.01; one factor ANOVA). Data 
are shown as means 土 S.E.M. (shown by vertical bars) of weight expressed in gram. 
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Figure 6.2.3 
Effects of 14 days oral administration of LS on body weight of adjuvant-induced 
monoarthritic rats. LS (0.5 g/kg/day) was administered to the rats 7 days before and 7 
days after induction of monoarthritis on day 0. There was no significant difference in 
body weight throughout the duration of the experiment. Data are shown as means ± 
S.E.M. (shown by vertical bars) of weight expressed in gram. 
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Figure 6.2.4 
Effects of 14 days oral administration of saline on body weight of adjuvant-induced 
monoarthritic rats. Saline (1 ml/kg/day) was administered to the rats 7 days before and 
7 days after induction of monoarthritis on day 0. A significant increase in body weight 
was found on days 0, 3，5, 6 and 7 (*P<0.05, **P<0.01, •**P<0.001; one factor 
ANOVA). Data are shown as means 土 S.E.M. (shown by vertical bars) of weight 
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Figure 6.2.5 
Effects of 14 days oral administration of Dex on knee joint sizes of adjuvant-induced 
monoarthritic rats. Dex (0.01 mg/kg/day) was administered to the rats 7 days before 
and 7 days after induction of monoarthritis. There was significant difference in knee 
joint sizes between FCA-injected knees of rats with and without Dex treatment; the 
former had reduced swelling (n=4-8; *P<0.05; two factor ANOVA), but were still 
more swollen than their contralateral saline-injected knees (**P<0.01; two factor 
ANOVA). There was no significant difference in knee joint sizes between 
contralateral saline-injected knees of rats with and without Dex treatment (P>0.05; 
two factor ANOVA). Bonferroni post-hoc tests: #尸<0.05，拥P<0.01,酒PcO.OOl 
(FCA-injected knees with Dex treatment vs without);"""尸<0.01, +++P<0.001 
(FCA-injected knees with Dex treatment vs their contralateral saline-injected knees). 
Data are shown as means 土 S.E.M. (shown by vertical bars) of knee joint sizes 
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Figure 6.2.6 
Effects of 14 days oral administration of dexamethasone (Dex) on knee joint sizes of 
adjuvant-induced monoarthritic rats. Dex (0.1 mg/kg/day) was administered to the rats 
7 days before and 7 days after induction of monoarthritis. There was significant 
difference in knee joint sizes between FCA-injected knees of rats with and without 
Dex treatment; the former had reduced swelling (n=5-8; *P<0.05; two factor 
ANOVA)，but were still more swollen than their contralateral saline-injected knees 
(***P<0.001; two factor ANOVA). There was no significant difference in knee joint 
sizes between contralateral saline-injected knees of rats with and without Dex 
treatment (P>0.05; two factor ANOVA). Bonferroni post-hoc tests: V<0.05, 
#蔣尸<0.001 (FCA-injected knees with Dex treatment vs without); +++P<0.001 
(FCA-injected knees with Dex treatment vs their contralateral saline-injected knees). 
Data are shown as means 土 S.E.M. (shown by vertical bars) of knee joint sizes 
expressed in percentage change. 
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Figure 6.2.7 
Effects of 14 days oral administration of LS on knee joint sizes of adjuvant-induced 
monoarthritic rats. LS (0.5 g/kg/day) was administered to the rats 7 days before and 7 
days after induction of monoarthritis. There was significant difference in knee joint 
sizes between FCA-injected knees of rats with and without LS treatment; the former 
had reduced swelling (n=9 for both; *P<0.05; two factor ANOVA), but were still 
more swollen than their contralateral saline-injected knees (***P<0.001; two factor 
ANOVA). There was no significant difference in knee joint sizes between 
contralateral saline-injected knees of rats with and without LS treatment (n=9; P>0.05; 
two factor ANOVA). Bonferroni post-hoc tests: V<0.05, #蔣戶<0.001 (FCA-injected 
knees with LS treatment vs without); +++尸<0.001 (FCA-injected knees with LS 
treatment vs their contralateral saline-injected knees). Data are shown as means 土 




.y 50- I FCA + Sal (1 ml/kg/day) "I "j 
芒 40- ^ ^ ^ ^ ~ - O r Sal + Sal (1 ml/kg/day) nS • 
t ： Z ^ f F ^ = ]ns # +++ 
c 10- / 
I 0- • • [> iQ >43 Q 0 
^ -10-
o 
-20 I 1 1 1 1 1 1 1 1 
-1 0 1 2 3 4 5 6 7 8 
Days post FCA injection 
Figure 6.2.8 
Effects of 14 days oral administration of saline on knee joint sizes of 
adjuvant-induced monoarthritic rats. Saline (1 ml/kg/day) was administered to the rats 
7 days before and 7 days after induction of monoarthritis. There was no significant 
difference in knee joint sizes between FCA-injected knees of rats with and without 
saline treatment (n=5-8 for both; P>0.05; two factor ANOVA). Knee joint sizes of 
their contralateral saline-injected knees were also not significantly different (尸〉0.05; 
two factor ANOVA), but they were smaller than their respective FCA-injected knees 
C**P<0.001; two factor ANOVA). Bonferroni post-hoc tests: +++P<0.001 
(FCA-injected knees with saline treatment vs their contralateral saline-injected knees). 
Data are shown as means 土 S.E.M. (shown by vertical bars) of knee joint sizes 
expressed in percentage change. 
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Figure 6.2.9 
Effects of 14 days oral administration of Dex on knee extension angles that provoked 
struggling behaviour in adjuvant-induced monoarthritic rats. Dex (0.01 mg/kg/day) 
was administered to the rats 7 days before and 7 days after induction of monoarthritis. 
There was significant difference in knee extension angles that provoked struggling 
behaviour in FCA-injected knees of rats with and without Dex treatment (n=4-8; 
**P<0.01; two factor ANOVA). Extension angles of their contralateral saline-injected 
knees were not significantly different (P>0.05; two factor ANOVA), but they required 
to be extended much greater than their respective FCA-injected knees to produce 
struggling behaviour (*P<0.05 for both; two factor ANOVA). Bonferroni post-hoc 
tests: #P<0.05’ 蔣尸<0.01,漏PcO.OOl (FCA-injected knees with Dex treatment vs 
without); +P<0.05，++P<0.01 (FCA-injected knees with Dex treatment vs their 
contralateral saline-injected knees). Data are shown as means 土 S.E.M. (shown by 
vertical bars) of changes in extension angle expressed in percentage change. 
148 
？ e 40] 
o l 3 � -
O) g 20- -«- FCA + Dex (0.1 mg/kg/day) "j * 
而 £ 10- - O Sal + Dex (0.1 mg/kg/day) 
•i . E 0 - —Q Q 寺 FCA J 1 n s 
> i j M J 
？ c -30- Y #+#/ ## 
•思 I \ ++ 1 
O) 3 -50- ^ 
-60- I"""""^ 
。一-70"! 1 1 1——I 1 1 1 1——I 
-1 0 1 2 3 4 5 6 7 8 
Days post FCA injection 
Figure 6.2.10 
Effects of 14 days oral administration of Dex on knee extension angles that provoked 
struggling behaviour in adjuvant-induced monoarthritic rats. Dex (0.1 mg/kg/day) was 
administered to the rats 7 days before and 7 days after induction of monoarthritis. 
There was significant difference in knee extension angles that provoked struggling 
behaviour in FCA-injected knees of rats with and without Dex treatment (n=5-8; 
***P<0.001; two factor ANOVA). Extension angles of their contralateral 
saline-injected knees were not significantly different (P>0.05; two factor ANOVA), 
but they required to be extended much greater than their respective FCA-injected 
knees to produce struggling behaviour (*P<0.05; two factor ANOVA). Bonferroni 
post-hoc tests: *V<0.01,画PcO.OOl (FCA-injected knees with Dex treatment vs 
without); +P<0.05, ++P<0.01 (FCA-injected knees with Dex treatment vs their 
contralateral saline-injected knees). Data are shown as means 土 S.E.M. (shown by 
vertical bars) of changes in extension angle expressed in percentage change 
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Figure 6.2.11 
Effects of 14 days oral administration of LS on knee extension angles that provoked 
struggling behaviour in adjuvant-induced monoarthritic rats. LS (0.5 g/kg/day) was 
administered to the rats 7 days before and 7 days after induction of monoarthritis. 
There was no significant difference in knee extension angles that provoked struggling 
behaviour in FCA-injected knees of rats with and without LS treatment (n=9 for both; 
P>0.05; two factor ANOVA). Extension angles of their contralateral saline-injected 
knees were also not significantly different (P>0.05; two factor ANOVA), but they 
required to be extended much greater than their respective FCA-injected knees to 
produce struggling behaviour (***P<0.001 for both; two factor ANOVA). Bonferroni 
post-hoc tests: ++/^<0.01，尸cO.OOl (FCA-injected knees with LS treatment vs 
their contralateral saline-injected knees). Data are shown as means 土 S.E.M. (shown 
by vertical bars) of changes in extension angle expressed in percentage change. 
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Figure 6.2.12 
Effects of 14 days oral administration of saline on knee extension angles that 
provoked struggling behaviour in adjuvant-induced monoarthritic rats. Saline (1 
ml/kg/day) was administered to the rats 7 days before and 7 days after induction of 
monoarthritis. There was no significant difference in knee extension angles that 
provoked struggling behaviour in FCA-injected knees of rats with and without saline 
treatment (n=5-8; P>0.05; two factor ANOVA). Extension angles of their 
contralateral saline-injected knees were also not significantly different (P>0.05; two 
factor ANOVA), but they required to be extended much greater than their respective 
FCA-injected knees to produce struggling behaviour (***P<0.001 for both; two factor 
ANOVA). Bonferroni post-hoc tests: ++P<0.01, + 杆尸<0.001 (FCA-injected knees with 
LS treatment vs their contralateral saline-injected knees). Data are shown as means 土 
S.E.M. (shown by vertical bars) of changes in extension angle expressed in 
percentage change. 
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Figure 6.2.13 
Effects of 14 days oral administration of Dex, LS or saline on knee joint blood flow of 
adjuvant-induced monoarthritic rats. Dex (0.01 mg/kg/day or 0.1 mg/kg/day), LS (0.5 
g/kg/day) or saline (1 ml/kg/day) was administered to the rats 7 days before and 7 
days after induction of monoarthritis. Compared with the control rats that had no oral 
treatment, high dose Dex (0.1 mg/kg/day) or LS produced significant reduction in 
blood flow in the FCA-injected knees (n=5-9; *P<0.05 and **P<0.01, respectively; 
unpaired r-test) but low dose Dex (0.01 mg/kg/day) or saline had no insignificant 
effect (n=4-8; F>0.05 for both; unpaired r-test). Data are shown as means 土 S.E.M. 
(shown by vertical bars) of changes in blood flow expressed in flux. 
152 
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Figure 6.2.14 
Cell infiltration in synovial tissues of FCA-injected test knees (A) and 
saline-injected contralateral knees (B) of rats with no oral treatment (control) (a), and 
with 14 days oral administration of 0.01 mg/kg/day Dex (b), 0.1 mg/kg/day Dex (c), 
0.5 g/kg/day LS (d), and 1 ml/kg/day saline (e). Magnification = 5X. 
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Figure 6.2.17 
Effects of 14 days oral administration of Dex, LS or saline on cell infiltration in 
synovial tissues of FCA-injected test knees (A) and saline-injected contralateral knees 
of rats (B). Oral administrations of drugs were given daily. Compared with control 
rats that had no oral treatment, cell infiltration levels were significant reduced in 
FCA-injected knees of rats treated with low or high dose Dex (n=4-8; ***P<0.001 for 
both; paired r-test) and LS (n=8-9; ***P<0.001; paired Mest). Cell infiltration levels in 
contralateral saline-injected knees of rats treated with low and high dose Dex (n=4-8; 
**P<0.01 and ***P<0.001, respectively; paired r-test) were also reduced compared 
with control. 
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(A) FeA-injected (test) knees (B) Saline-injected (contralateral) knees 
(a) FCA (a) Saline 
(b) Dex (0.01 mg/kg/day) (b) Dex (0.01 mg/kg/day) 
(c) Dex (0.1 mg/kg/day) (c) Dex (0.1 mg/kg/day) 
(d) LS (0.5 g/kg/day) (d) LS (0.5 g/kg/day) 
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Figure 6.2.16 
Synovial tissue proliferation of FCA-injected test knees (A) and saline-injected 
contralateral knees of rats (B) with no oral treatment (control) (a), and with 14 days 
oral administration of 0.01 mg/kg/day Dex (b), 0.1 mg/kg/day Dex (c), 0.5 g/kg/day 
LS (d), and 1 ml/kg/day saline (e). Magnification = 2.5X. 
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Effects of 14 days oral administration of Dex, LS or saline on synovial tissue 
proliferation of FCA-injected test knees (A) and saline-injected contralateral knees of 
rats (B). Oral administrations of drugs were given daily. Compared with control rats 
that had no oral treatment, there was significant reduction in synovial tissue 
proliferation in FCA-injected knees of rats treated with high dose Dex (n=4-8; 
*P<0.05; paired r-test). There was no significant difference in the level of synovial 
tissue proliferation in contralateral saline-injected knees of all treatment groups 
(n=4-8; P>0.05 for all; paired Mest). 
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Figure 6.2.18 
Cartilage degradation of FCA-injected test knees (A) and saline-injected contralateral 
knees (B) of rats with no oral treatment (control) (a), and with 14 days oral 
administration of 0.01 mg/kg/day Dex (b), 0.1 mg/kg/day Dex (c), 0.5 g/kg/day LS (d), 
and 1 ml/kg/day saline(e). Magnification = 5X. 
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Effects of 14 days oral administration of Dex, LS or saline on cartilage degradation of 
FCA-injected test knees (A) and saline-injected contralateral knees of rats (B). Oral 
administrations of drugs were given daily. Compared with control rats that had no oral 
treatment, cartilage degradation levels were significantly reduced in FCA-injected 
knees of rats treated with low and high doses of Dex (n=4-8; *P<0.05 and **P<0.01， 
respectively; paired r-test) or LS (n=8-9; ***P<0.001; paired r-test). Contralateral 
saline-injected knees of all treatment groups showed negligible cartilage degradation 
(n=4-8; P>0.05; paired Mest). 
6.3 Oral administration of LS for 13 days after induction of arthritis 
6.3.1 Method 
Sprague-Dawley rats (250-300 g) were anaesthetized with intra-peritoneal injections 
of 40 mg/kg thiopentone on day 0, and then on each rat, one knee joint was injected 
with 0.125 ml Freund's complete adjuvant (FCA) containing 0.125 mg 
Mycobacterium tuberculosis while the contralateral knee was injected with 0.125 ml 
(0.9%) physiological saline. 
For the first and the second groups of rats, dexamethasone (0.1 mg/kg/day or 1 
mg/kg/day) was administered to the rats daily by oral route for 13 days after induction 
of arthritis. For the third group of rats, LS (0.5 g/kg/day) was given by the same 
protocol. 
The body weight, knee extension angle that provoked struggling behaviour, and knee 
joint size of the rats were measured on day 0 prior to induction of arthritis, and on 
days 1，2, 3, 4, 7，9, 11 and 14 after induction of arthritis, while knee joint blood flow 
was measured on day 14; these correspond to indexes of algesia, oedema and 
hyperaemia, respectively. At the end of the experiment, the knee joints were excised 
and processed for histological examination (for details, see previous Methods Section 
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on page 47). Histological scores on the extent of cell infiltration, tissue proliferation, 
and erosions of cartilage and bone in the knee joints were used as additional indexes 
of the arthritis condition. 
6.3.2 Results 
6.3.2.1 Body weight 
There was a significant reduction in body weight of rats after dexamethasone 
administration (0.1 mg/kg/day and 1 mg/kg/day) from day 2 onwards (P<0.05 -
P<0.001 for both; one-factor ANOVA). On the other hand, the body weight 
significantly increased from day 9 onwards after LS (0.5 g/kg/day) treatment (P<0.01 
-P<0.001; one-factor ANOVA). These results are shown in Figures 6.3.1 - 6.3.3. 
6.3.2.2 Knee joint size 
The swelling of FCA-injected knees after oral administration of low dose 
dexamethasone (0.1 mg/kg/day) were similar to control rats that had not received oral 
treatment (n=5-8;尸〉0.05; two factor ANOVA). Contralateral saline-injected knees of 
the dexamethasone treated rats were significantly smaller than those of the control rats 
from day 4 onwards (尸<0.001; two factor ANOVA;尸<0.05,尸<0.001; Bonferroni 
post-hoc tests), and they were significantly smaller than their respective FCA-injected 
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knees from day 1 onwards (PcO.OOl; two factor ANOVA; PcO.OOl; Bonferroni 
post-hoc tests). These results are shown in Figure 6.3.4. 
The swelling of FCA-injected knees in rats treated with high dose dexamethasone (1 
mg/kg/day) was reduced compared with control rats that had not received oral 
treatment (n=8;尸<0.05; two factor ANOVA); the reduction was significant from day 
2 onwards (P<0.05, P<0.01，P<0.001; Bonferroni post-hoc tests). Knee joint sizes of 
the contralateral saline-injected knees of dexamethasone treated rats were 
significantly smaller than those of the control rats from day 1 onwards (PcO.OOl; two 
factor ANOVA; P<0.05, PcO.OOl; Bonferroni post-hoc tests), and they were smaller 
than their respective FCA-injected knees (P<0.001; two factor ANOVA). These 
results are shown in Figure 6.3.5. 
The swelling of FCA-injected knees after oral administration of LS (0.5 g/kg/day) 
were similar to those of control rats that had not received oral treatment (n=6-8; 
P>0.05; two factor ANOVA). Knee joint sizes of their contralateral saline-injected 
knees were also similar (P<0.05; two factor ANOVA), and they were significantly 
smaller than their respective FCA-injected knees from day 1 onwards (PcO.OOl; two 
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factor ANOVA; PcO.OOl; Bonferroni post-hoc tests). These results are shown in 
Figure 6.3.6. 
6.3.2.3 Knee extension angle 
Knee extension angles that provoked struggling behaviour were not significantly 
different in FCA-injected knees of rats with and without treatment of low dose 
dexamethasone (0.1 mg/kg/day) (n=5-8;尸〉0.05; two factor ANOVA). There was also 
no significant difference between extension angles of their contralateral 
saline-injected knees (P>0.05; two factor ANOVA), but they required to be extended 
much greater than their respective FCA-injected knees to produce struggling 
behaviour (PcO.OOl; two factor ANOVA). These results are shown in Figure 6.3.7. 
The FCA-injected knees of rats treated with high dose dexamethasone (1 mg/kg/day) 
required to be extended much greater than those without dexamethasone treatment to 
produce struggling behaviour (n=8; PcO.OOl; two factor ANOVA); extension angles 
of the dexamethasone treated group were significantly larger from day 2 to day 9 
(P<0.001; Bonferroni post-hoc tests) and they were not significantly different from 
those of their contralateral saline-injected knees from day 4 onwards. Extension 
angles of the contralateral saline-injected knees of these two groups of rats were not 
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significantly different (P>0.05; two factor ANOVA), but they required to be extended 
much greater than their respective FCA-injected knees to produce struggling 
behaviour (P<0.001; two factor ANOVA). These results are shown in Figure 6.3.8. 
LS (0.5 g/kg/day) did not alleviate pain in the FCA-injected knees compared to those 
without LS treatment (n=6-8; P>0.05; two factor ANOVA). Extension angles of the 
contralateral saline-injected knees of these two groups of rats were also not 
significantly different (P>0.05; two factor ANOVA), but they required to be extended 
much greater than their respective FCA-injected knees to produce struggling 
behaviour from day 1 to day 9 (尸<0.001; two factor ANOVA; PcO.Ol, PcO.OOl; 
Bonferroni post-hoc tests). These results are shown in Figure 6.3.9. 
6.3.2.4 Knee joint blood flow 
As shown in Figure 6.3.10, there was a significant reduction in blood flow of 
FCA-injected knees of rats treated with high dose dexamethasone (1 mg/kg/day) 
(n=5-8; P<0.05; unpaired r-test), but not in those treated with low dose 
dexamethasone (0.1 mg/kg/day) (n=5-8; P>0.05; unpaired r-test) or LS (0.5 g/kg/day) 
(n=6-8; P>0.05; unpaired r-test). 
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6.3.2.5 Histological evaluation 
6.3.2.5.1 Cell infiltration 
As shown in the micrographs in Figure 6.3.11 A and in Figure 6.3.12A, the level of 
cell infiltration in FCA-injected knees of rats treated with 13 days oral administration 
of dexamethasone (1 mg/kg/day) was significantly lower than that in control rats that 
had not received oral treatment (n=8;尸<0.001; paired r-test). However, treatment 
with low dose Dex (0.1 mg/kg/day) or LS (0.5 g/kg/day) did not significantly affect 
the level of cell infiltration in the FCA-injected knees of these animals, compared to 
that of the control group (n=6-8; P>0.05 for both; paired r-test). 
The level of cell infiltration in contralateral saline-injected knees of control rats 
without oral treatment was not significantly different to that treated with 
dexamethasone (尸〉0.05; paired Mest), but LS treated animals showed a significant 
small increase (尸<0.05; paired r-test). These results are shown in Figs. 6.3.1 IB and 
6.3.12B. 
6.3.2.5.2 Synovial tissue proliferation 
There was no significant difference in the level of synovial tissue proliferation in 
FCA-injected knees of control rats without oral treatment compared with those treated 
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with dexamethasone or LS (n=6-8; F>0.05 for both; paired /-test). Synovial tissue 
proliferation in contralateral saline-injected knees of the four groups of animals was 
small, and there was no difference between control rats and those that had received 
low dose dexamethasone (0.1 mg/kg/day) or LS (n=6-8; P>0.05 for both; paired 
/-test), but rats treated with high dose dexamethasone (1 mg/kg/day) showed reduced 
synovial tissue proliferation (n=8; /^<0.01; paired /-test). These results are shown in 
the micrographs in Figure 6.3.13 and in Figure 6.3.14. 
6.3.2.5.3 Cartilage degradation 
Cartilage degradation in FCA-injected knees of control rats treated without oral 
treatment was similar to those found in rats treated with low dose dexamethasone (0.1 
mg/kg/day) and LS (n=6-8; P>0.05 for both; paired /-test), but rats treated with high 
dose dexamethasone (1 mg/kg/day) showed reduced cartilage degradation (n=8; 
P<0.01; paired /-test). No significant cartilage degradation was observed in 
contralateral saline-injected knees of all these groups of animals (n=6-8; i^0.05; 
paired /-test), except for the LS treated group that showed a small but significant 
degree of cartilage degradation (n=6-8; P>0.05; paired /-test). These results are shown 
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Figure 6.3.1 
Effects of 13 days oral administration of dexamethasone (Dex) on body weight of 
adjuvant-induced monoarthritic rats. Dex (0.1 mg/kg/day) was administered to the rats 
for 13 days after induction of monoarthritis on day 0. There were significant 
reductions in body weight from day 2 onward (*P<0.05，**P<0.01，••*P<0.001; 
one-factor ANOVA). Data are shown as means 土 S.E.M. (shown by vertical bars) of 
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Figure 6.3.2 
Effects of 13 days oral administration of Dex on body weight of adjuvant-induced 
monoarthritic rats. Dex (1 mg/kg/day) was administered to the rats for 13 days after 
induction of monoarthritis on day 0. There were significant reductions in body weight 
from day 2 onward (***P<0.001; one-factor ANOVA). Data are shown as means 土 
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Figure 6.3.3 
Effects of 13 days oral administration of LS on body weight of adjuvant-induced 
monoarthritic rats. LS (0.5 g/kg/day) was administered to the rats for 13 days after 
induction of monoarthritis on day 0. The body weight increased significantly from 
day 9 (*•戶<0.01，***P<0.001; one-factor ANOVA). Data are shown as means 土 
S.E.M. (shown by vertical bars) of weight expressed in gram. 
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Figure 6.3.4 
Effects of 13 days oral administration of Dex on knee joint sizes of adjuvant-induced 
monoarthritic rats. Dex (0.1 mg/kg/day) was administered to the rats for 13 days after 
induction of monoarthritis on day 0. There was no significant difference in knee joint 
sizes between FCA-injected knees with and without Dex treatment (n=5-8; P>0.05; 
two factor ANOVA). Knee joint sizes of the contralateral saline-injected knees of Dex 
treated group were significantly smaller than those without Dex treatment 
(***尸<0.001; two factor ANOVA), and both were smaller than their respective 
FCA-injected knees (***P<0.001; two factor ANOVA). Bonferroni post-hoc tests: 
+++尸<0.001 (FCA-injected knees with Dex treatment vs their contralateral 
saline-injected knees); A 尸 < 0 . 0 5 ， ( c o n t r a l a t e r a l saline-injected knees with 
Dex treatment vs without). Data are shown as means 土 S.E.M. (shown by vertical bars) 
of knee joint sizes expressed in percentage change. 
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Figure 6.3.5 
Effects of 13 days oral administration of Dex on knee joint sizes of adjuvant-induced 
monoarthritic rats. Dex (1 mg/kg/day) was administered to the rats for 13 days after 
induction of monoarthritis on day 0. There was significant difference in knee joint 
sizes between FCA-injected knees of rats with and without Dex treatment (n=8; 
*P<0.05; two factor ANOVA); the former group had reduced swelling. Knee joint 
sizes of their contralateral saline-injected knees were also significantly different 
(***P<0.001; two factor ANOVA); sizes of the former group were smaller, and both 
were smaller than their respective FCA-injected knees (***P<0.001; two factor 
ANOVA). Bonferroni post-hoc tests: *P<0.05, ^P<0.01, *^P<0.001 (FCA-injected 
knees with Dex treatment vs without); ++尸<0.01，+++P<0.001 (FCA-injected knees 
with Dex treatment vs their contralateral saline-injected knees); A尸<0.05, 
(contralateral saline-injected knees with Dex treatment vs without). Data are shown as 
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Figure 6.3.6 
Effects of 13 days oral administration of LS on knee joint sizes of adjuvant-induced 
monoarthritic rats. LS (0.5 g/kg/day) was administered to the rats for 13 days after 
induction of monoarthritis on day 0. There was no significant difference in knee joint 
sizes between FCA-injected knees of rats with and without LS treatment (n=6-8; 
P>0.05; two factor ANOVA). Knee joint sizes of their contralateral saline-injected 
knees were also not significantly different (尸>0.05; two factor ANOVA), but they 
were smaller than their respective FCA-injected knees (•**P<0.001; two factor 
ANOVA). Bonferroni post-hoc tests: +++P<0.001 (FCA-injected knees with LS 
treatment vs their contralateral saline-injected knees). Data are shown as means 土 
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Figure 6.3.7 
Effects of 13 days oral administration of Dex on knee extension angles that provoked 
struggling behaviour in adjuvant-induced monoarthritic rats. Dex (0.1 mg/kg/day) was 
administered to the rats for 13 days after induction of monoarthritis on day 0. There 
was no significant difference in knee extension angles that provoked struggling 
behaviour in FCA-injected knees with and without Dex treatment (n=5-8; P>0.05; 
two factor ANOVA). Extension angles of their contralateral saline-injected knees 
were also not significantly different (P>0.05; two factor ANOVA), but they required 
to be extended much greater than their respective FCA-injected knees to produce 
struggling behaviour (***P<0.001; two factor ANOVA). Bonferroni post-hoc tests: 
++P<0.01, + 付尸<0.001 (FCA-injected knees with Dex treatment vs their contralateral 
saline-injected knees). Data are shown as means 土 S.E.M. (shown by vertical bars) of 
changes in extension angle expressed in percentage change. 
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Figure 6.3.8 
Effects of 13 days oral administration of Dex on knee extension angles that provoked 
struggling behaviour in adjuvant-induced monoarthritic rats. Dex (1 mg/kg/day) was 
administered to the rats for 13 days after induction of monoarthritis on day 0. There 
was significant difference in knee extension angles that provoked struggling 
behaviour in FCA-injected knees of rats with and without Dex treatment (n=8; 
***P<0.001; two factor ANOVA). Extension angles of their contralateral 
saline-injected knees were not significantly different ( P � 0 . 0 5 ; two factor ANOVA), 
but they required to be extended much greater than their respective FCA-injected 
knees to produce struggling behaviour (***P<0.05; two factor ANOVA). Bonferroni 
post-hoc tests: ###P<0.001 (FCA-injected knees with Dex treatment vs without); 
++P<0.01，"^^<0.001 (FCA-injected knees with Dex treatment vs their contralateral 
saline-injected knees). Data are shown as means 土 S.E.M. (shown by vertical bars) of 
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Figure 6.3.9 
Effects of 13 days oral administration of Dex on knee extension angles that provoked 
struggling behaviour in adjuvant-induced monoarthritic rats. LS (0.5 g/kg/day) was 
administered to the rats for 13 days after induction of monoarthritis on day 0. There 
was no significant difference in knee extension angles that provoked struggling 
behaviour in FCA-injected knees of rats with and without LS treatment (n=6-8; 
P>0.05; two factor ANOVA). Extension angles of their contralateral saline-injected 
knees were also not significantly different (P>0.05; two factor ANOVA), but they 
required to be extended much greater than their respective FCA-injected knees to 
produce struggling behaviour (***P<0.001; two factor ANOVA). Bonferroni post-hoc 
tests: ++P<0.01’ (FCA-injected knees with Dex treatment vs their 
contralateral saline-injected knees). Data are shown as means 土 S.E.M. (shown by 
vertical bars) of changes in extension angle expressed in percentage change. 
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Figure 6.3.10 
Effects of 13 days oral administration of Dex or LS on knee joint blood flow of 
adjuvant-induced monoarthritic rats. Dex (0.1 mg/kg/day or 1 mg/kg/day) or LS (0.5 
g/kg/day) was administered to the rats for 13 days after induction of monoarthritis. 
There was a significant reduction in blood flow of FCA-treated knees in rats treated 
with high dose Dex (1 mg/kg/day) (n=5-8; *P<0.05; unpaired r-test), but not in those 
treated with low dose Dex (0.1 mg/kg/day) (n=5-8; P>0.05; unpaired r-test) or LS (0.5 
g/kg/day) (n=6-8; P>0.05; unpaired r-test). Data are shown as means 土 S.E.M. (shown 
by vertical bars) of changes in blood flow expressed in flux. 
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Figure 6.3.15 
Cell infiltration in synovial tissues of FCA-injected test knees (A) and saline-injected 
contralateral knees (B) of rats without oral treatment (a) and with 13 days oral 
administration of 0.1 mg/kg/day Dex (b), 1 mg/kg/day Dex (c), and 0.5 g/kg/day LS 
(d). High dose Dex reduced cell infiltration level in the FCA-injected knee. 
Magnification = 5X. 
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Figure 6.3.15 
Effects of 13 days oral administration of Dex or LS on cell infiltration in synovial 
tissues of FCA-injected test knees (A) and saline-injected contralateral knees (B) of 
rats. Oral administrations of drugs were given daily. Compared with control rats that 
had not received oral treatment, high dose Dex (1 mg/kg/day) reduced cell infiltration 
in the FCA-injected knees (n=8; ***P<0.001; paired r-test), and LS (0.5 g/kg/day) 
produced a small but significant increase in cell infiltration in the saline-injected 
contralateral knees (n=6-8; *P<0.05; paired r-test). 
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(A) FeA-injected (test) knees (B) Saline-injected (contralateral) knees 
(a) FCA (a) Saline 
(b) Dex (0.1 mg/kg/day) (b) Dex (0.1 mg/kg/day) 
(c) Dex (1 mg/kg/day) (c) Dex (1 mg/kg/day) 
(d) LS (0.5 g/kg/day) (d) LS (0.5 g/kg/day) 
186 
Figure 6.3.15 
Synovial tissue proliferation of FCA-injected test knees (A) and saline-injected 
contralateral knees (B) of rats without oral treatment (a) and with 13 days oral 
administration of 0.1 mg/kg/day Dex (b), 1 mg/kg/day Dex (c), and 0.5 g/kg/day LS 
(d). Magnification = 2.5X. 
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Figure 6.3.15 
Effects of 13 days oral administration of Dex or LS on synovial tissue proliferation of 
FCA-injected test knees (A) and saline-injected contralateral knees (B) of rats. Oral 
administrations of drugs were given daily. Compared with control rats that had not 
received oral treatment, there was no significant change in synovial tissue 
proliferation in FCA-injected knees after all these treatments (n=4-8; P>0.05; paired 
r-test), but a significant small reduction in synovial tissue proliferation was detected in 
contralateral saline-injected knees of rats treated with high dose Dex (n=8; **P<0.01; 
paired r-test). 
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Cartilage degradation of FCA-injected test knees (A) and saline-injected contralateral 
knees (B) of rats without oral treatment (a) and with 13 days oral administration of 
0.1 mg/kg/day Dex (b), 1 mg/kg/day Dex (c), and 0.5 g/kg/day LS (d). Magnification 
= 5X. 
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Figure 6.3.16 
Effects of 13 days oral administration of Dex or LS on cartilage degradation of 
FCA-injected test knees (A) and saline-injected contralateral knees (B) of rats. Oral 
administrations of drugs were given daily. Compared with control rats that had not 
received oral treatment, there was a significant decrease in cartilage degradation in 
FCA-injected knees of rats treated with high dose Dex (n=8; **P<0.01; paired r-test), 
and a small but significant increase in cartilage degradation was detected in 
contralateral saline-injected knees of rats treated with LS (n=6-8; *P<0.05; paired 
r-test). 
6.4 Discussions 
Traditional Chinese medicines are commonly taken orally. The Lingzhi and Sen Miao 
San (LS) formulation used in the present study is in the form of capsule for oral 
administration. In order to mimic the actual therapeutic oral route of administration, 
the antiarthritis efficacy of oral administration of LS was investigated in the present 
study. 
This is the first study investigating the anti-inflammatory effect of LS in animals, so 
the effective dose of LS is not known. In the hope of producing maximum effect, the 
maximum amount of LS (0.5 g/ml) that could be suspended in saline was used. This 
suspension was administered orally to the rats (0.3 ml/300g rat) daily for 6 days after 
induction of arthritis (equivalent to 0.5 g/kg/day). This produced no improvement of 
the arthritic symptoms, which include joint swelling, pain and hyperaemia, suggesting 
that the dose of 0.5 g/kg/day LS used might be too low to exert anti-inflammatory and 
analgesic effects. Therefore, the study was repeated using a higher dose of 1 g/kg/day 
of LS (by feeding the rats with LS at the dose of 0.5 g/kg twice a day). However, such 
treatment also produced no change on the arthritis symptoms. It is not possible to 
further increase the dose of LS used due to its limited solubility. According to the 
literature, the human daily dosage of Cortex Phellodendri, Atractylodisa Rhizoma and 
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Radix Achymnthis Bidentatae is about 3-9 g each. Several reports have demonstrated 
that G. lucidum was not cytotoxic and appeared to be very safe because oral 
administration of the extract did not display any toxicity (Eo et al., 1999; Liu et al., 
2004; Liu et al., 2002; Zhu, 1998). As the total accumulated dose over the 6 days 
treatment of 1 g/kg/day of LS was quite high compared to the recommended daily 
human consumption, this argues against the lack of efficacy of LS is due to 
insufficient quantity of LS administered. 
It is well known that many traditional Chinese medicines required to be taken for a 
long period before improvement of disease symptoms can be observed. Various 
projects studying the anti-inflammatory effects of traditional Chinese medicines in 
adjuvant-induced arthritic models usually investigate their effects after administration 
for 2 weeks (Fan et al., 2005; Harigai et aL, 1995; Jia et al., 2003). Therefore, the lack 
of an ti arthritis efficacy of LS in the above studies might be due to the treatment time 
being too short. This hypothesis was tested by two approaches: for the first approach, 
LS (0.5 g/kg/day) was administered to the rats daily by oral route for 7 days before 
and 7 days after induction of arthritis, and for the second approach, LS (0.5 g/kg/day) 
was administered to the rats daily by oral route for 13 days after induction of arthritis. 
195 
By the first approach, LS reduced joint swelling and hyperaemia in the FCA-injected 
knees. Histological examinations of the joint tissues further revealed that it 
ameliorated the pathological changes that include infiltration of inflammatory cells 
and erosions of cartilage in the joints. This confirmed that LS possesses 
anti-inflammatory effects. On the other hand, the negative control group that received 
oral administration of saline instead of drugs did not show any improvement in 
arthritic symptoms. In fact, the arthritis symptoms in these rats with oral saline 
treatment were not statistically different to those found in rats without oral saline 
administration. Therefore, to be consistent with other studies in the present project, 
FCA-injected rats without oral saline treatment were used as the control group. 
Cytokines like interleukin-1, interleukin-6 and TNF-a are important mediators of 
inflammation (Firestein et al., 2000). Recent studies have revealed these 
pro-inflammatory cytokines play a key role in the pathogenesis and disease 
progression of RA (Gravallese et al., 2000a). The ultimate hallmark of RA is 
irreversible joint damage caused by cartilage destruction and bone erosion of the 
arthritic joints (Cai et al., 2005; Weyand, 2000). RA patients were shown to have 
higher levels of lL-1, IL-6 and TNF-a in synovial fluid and joint tissues (Cai et al., 
2006; Feldmann et al., 1990; Feldmann et al., 1996b). Some studies have shown that 
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the anti-arthritic effects of several Chinese herbal products involved inhibition of the 
local tissue cytokine pathways (Fan et al., 2005; Ho et al., 1999; Shin et al., 2003; 
Yeom et al., 2003). For example, PG201, an ethanol extract of a herbal formula, 
significantly inhibited the production of the pro-inflammatory mediators TNF-a and 
IL-1 in local arthritic tissues and suppressed the progression of collagen-induced 
arthritis in mice (Fan et al., 2005; Shin et al.’ 2003). It is uncertain whether the 
protective effects of LS on cartilage destruction in the present arthritis model are also 
due to inhibition of cytokine activities; these will have to be elucidated by further 
experiments. 
Ganoderma lucidum, which is one of the components of LS, is widely used in 
traditional Chinese medicine for the prevention and treatment of various kinds of 
diseases including arthritis and cancer (Liu et al., 2002). The polysaccharides, one of 
the major constituents of G. lucidum, were reported to have immunomodulating 
properties (Bao et al., 2001). Recent findings suggested that the antitumor effect of G. 
lucidum mediated by the polysaccharides was a consequence of the potentiation of 
cytokine production like IL-l, IL-6 and TNF-a (Liu et al., 2002; Wang et al., 1997). It 
is interesting to note that G. lucidum stimulates the production of these 
pro-inflammatory cytokines instead of the expected suppression. As mentioned earlier, 
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IL-1, IL-6 and TNF-a play important roles in inflammation (Firestein et al., 2000)，for 
example, EL-l and TNF-a are essential pro-inflammatory cytokines involved in bone 
and cartilage degradation. Therefore, an increase in cytokine production may 
deteriorate the RA condition. It should also be noted that some cytokines like IL-4 
and IL-IO have anti-inflammatory actions, which may be a result of inhibition of the 
production and/or activities of pro-inflammatory cytokines such as IL-1 and TNF-a, 
or enhancing the production of anti-inflammatory cytokines (Firestein et aL, 2000; 
Lubberts et al., 2003; St. Clair et al., 2004; van den Berg, 2001). The actions of LS on 
anti-inflammatory cytokines are unknown. 
Many traditional Chinese medicines are usually formulated with several herbal 
components having different physiological activity. There may be synergism among 
the component herbs that could influence their overall physiological action such that 
combination of two herbs may enhance each other's action or decrease the toxic effect 
of the partner herb (Xuejiang et al., 2001). The LS used in the present study consists 
of 4 different herbs. With the rationale mentioned above, perhaps the inhibition of 
pro-inflammatory cytokines and/or the production of anti-inflammatory cytokines 
stimulated by San Miao Sen is more prominent than the increased production of 
pro-inflammatory cytokine caused by G. lucidum, and therefore, the overall effect of 
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LS is anti-arthritic. This idea is supported by a recent report of Bao and colleagues on 
the same LS capsule as used in the present study, which demonstrated that LS 
significantly reduced ex-vivo production of the inflammatory cytokine IL-18 in 
rheumatoid arthritis patients (Bao et al., 2006). Therefore, LS is suggested to have 
beneficial immunomodulatory effect in patients with rheumatoid arthritis. 
Eicosanoids are among the most important mediators of the inflammatory reaction. 
The principal eicosanoids are the prostaglandins, the thromboxanes and the 
leukotrienes (Rang, 2003). Prostaglandins like PGE2 mediate the pain and oedema 
associated with arthritis. In eicosanoid generation, phospholipase A2 and 
cyclooxygenase have been described as important regulatory enzymes. The hydrolytic 
release of arachidonic acid from membrane phospholipids is initiated by 
phospholipase A2, and arachidonic acid is then catalysed by cyclooxygenase enzymes 
for the subsequent production of prostaglandins (Sampey et al., 2000). Many 
anti-inflammatory agents function by inhibiting these regulatory enzymes. NSAIDs 
block inflammation by inhibiting the activity of cyclooxygenase while glucocorticoids 
exhibit the anti-inflammatory effects by increasing the annexin expression, which 
inhibits phospholipase A2 thus blocking the arachidonic cascade, and decreasing the 
expression of COX-2 (Firestein et al, 2000; Kurumbail et al., 1996; Langenegger et 
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al., 1999; Moreland et al., 2002). One of the constituents of LS, G. lucidum, has also 
been shown to inhibit phospholipase A2 from bee venom and from hog pancreas (Li et 
al., 2007). This suggests inhibition of eicosanoids production could be another 
mechanism for the anti-inflammatory effects of LS. However, LS failed to show 
significant anti-inflammatory or immunomodulatory effects in a clinical trial on 
rheumatoid arthritis patients (Li et al., 2007)，but there was attributed to the dose of 
LS used was too low. 
Interestingly, oral treatment of LS by the second approach (i.e. administration of LS 
for 13 days post induction of arthritis) did not relieve the arthritis symptoms in the 
FCA-injected knees. Since the duration of LS administration is the same for the first 
and second administration approach, but only the first approach showed effective 
anti-inflammatory and analgesic activities, it can be deduced that LS possesses better 
an ti arthritic efficacy when administered prophylactically, i.e. before the induction of 
arthritis. Longer duration of LS treatment by the second approach was not tested 
because the present monoarthritis model showed resolution of the arthritis symptoms 
from two weeks onward after induction of arthritis. The testing of oral administration 
of LS for longer treatment period should be performed in a model of arthritic that 
could be sustained for long term, and one such example is a chronic unilateral arthritis 
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that could be developed by repeated intra-articular injections of FCA into the rat knee 
joints (Gauldie et al., 2004). Unfortunately, due to the time constraint of the present 
project, this part of the study was not investigated. 
Dexamethasone was used as positive control based on the fact that it has been proven 
to be an effective agent for inhibiting adjuvant-induced arthritis at a dose of 1 mg/kg 
po in rats (Tsao et al., 1997). After induction of arthritis, treatments with oral 
dexamethasone for 7 days or 13 days alleviated the arthritic symptoms including 
swelling, pain, hyperaemia, and cell infiltration in the FCA-injected knees. These 
findings are in agreement with a previous report that showed dexamethasone 
suppressed the swelling and histological changes associated with adjuvant-induced 
arthritis in the rat (Tsao et al.’ 1997). 
Rheumatoid arthritis, which is a chronic inflammatory disease with synovitis, is 
associated with weight loss and loss of lean body mass, called rheumatoid cachexia 
(Goodson et al., 2003; Roubenoff et al., 1997). Currently there is no established 
mechanism for rheumatoid cachexia, but it is accompanied by elevated resting energy 
expenditure, accelerated whole-body protein catabolism, and excess production of the 
inflammatory cytokines, TNF-a and IL-1 (Walsmith and Roubenoff, 2002). A loss of 
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>40% of existing lean body mass results in death (Goodson et al., 2003; Roubenoff et 
al, 1993). In the present study, it was found that rats suffered from severe weight loss 
during dexamethasone treatment, but no significant weight loss was detected in rats 
treated with LS. Therefore, the present monoarthritis model does not produce 
significant systemic side effect, but oral treatment with high dose dexamethasone 
treatment would aggravate the problem of weight loss, although it may cause weight 
gain in long-term treatment in human. More importantly, the preset findings showed 




Effects of intra-peritoneal administration of LS in 
adiuvant-induced monoarthritic rats 
Intra-peritoneal administration of LS for 7 days before and 7 days after 
induction of arthritis 
7.1 Method 
Sprague-Dawley rats (250-300 g) were anaesthetized with intra-peritoneal injections 
of 40 mg/kg thiopentone on day 0, and then on each rat, one knee joint was injected 
with 0.125 ml Freund's complete adjuvant (FCA) containing 0.125 mg 
Mycobacterium tuberculosis while the contralateral knee was injected with 0.125 ml 
(0.9%) physiological saline. 
For the first and the second groups of rats, dexamethasone (0.01 mg/kg/day or 0.1 
mg/kg/day) was administered to the rats daily by intra-peritoneal injection for 7 days 
before and 7 days after induction of arthritis. LS (0.05 g/kg/day) and saline (1 
ml/kg/day) were given to the third and fourth groups of rats by the same protocol. 
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The body weight, extension angle that provoked struggling behaviour and knee joint 
sizes of the rats were measured on days 0, 1, 2, 3, 4 and 7 while knee joint blood flow 
was measured on day 7 to provide indexes of algesia, oedema and hyperaemia, 
respectively. At the end of the experiment, the knee joints were excised and processed 
for histological examination (for details, see previous Methods Section on page 47). 
Histological scores on the extent of cell infiltration, tissue proliferation, and erosions 
of cartilage and bone in the knee joints were used as additional indexes of the arthritis 
condition. 
7,2 Results 
7.2.1 Body weight 
There was no significant difference in body weight of rats treated with intra-peritoneal 
injection of dexamethasone (0.01 mg/kg/day and 0.1 mg/kg/day) or LS (0.05 g/kg/day) 
(P>0.05; one factor ANOVA). However, in the saline-treated group, the body weight 
increased significantly on days -1’ 0, 5, 6 and 7 (P<0.05, P<0.01, P<0.001; one factor 
ANOVA). These results are shown in Figures 7.1 - 7.4. 
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7.2.2 Knee joint size 
The swelling of FCA-injected knees in rats treated with intra-peritoneal injection of 
low doses of dexamethasone (0.01 mg/kg/day) were similar to those in FCA-treated 
knees of rats that did not received dexamethasone treatment (n=4-8; P>0.05; two 
factor ANOVA). The knee joint sizes in the contralateral saline-injected knees of 
these two groups of animals were also similar (P�0.05; two factor ANOVA), but they 
were smaller than their respective FCA-injected knees from day 1 onwards (PcO.OOl; 
two factor ANOVA; PcO.OOl; Bonferroni post-hoc tests). These results are shown in 
Figure 7.5. 
The swelling of FCA-injected knees in rats treated with intra-peritoneal injection of 
high doses of dexamethasone (0.1 mg/kg/day) were less pronounced compared to 
those in FCA-treated knees of rats that did not received dexamethasone treatment 
(n=5-8; PcO.OOl; two factor ANOVA); the differences were significant from day 1 
onwards (PcO.OOl; Bonferroni post-hoc tests), but they were still more swollen than 
their contralateral saline-injected knees, especially from day 1 to day 4 (P<0.05 -
0.001; Bonferroni post-hoc tests). There was no significant difference in knee joint 
sizes between contralateral saline-injected knees of rats with and without 
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dexamethasone treatment (P>0.05; two factor ANOVA). These results are shown in 
Figure 7.6. 
Similarly, LS treatment reduced swelling of the FCA-injected knees compared with 
FCA-injected knees of rats without LS treatment from day 1 onwards (n=6-8; 
P<0.001; Bonferroni post-hoc tests). The contralateral saline-injected knees of these 
two groups of rats were not significantly different from each other (P>0.05; two 
factor ANOVA), but they were significantly smaller than their FCA-injected knees 
from day 1 onwards (P<0.001; Bonferroni post-hoc tests). These results are shown in 
Figure 7.7. 
The swelling of FCA-injected knees after intra-peritoneal injection of saline did not 
reduce compared with those without saline administration (n=7-8; P>0.05; two factor 
ANOVA). There was no significant difference between knee joint sizes of their 
contralateral saline-injected knees (P>0.05; two factor ANOVA), but they were 
smaller than their respective FCA-injected knees from day 1 onwards (PcO.OOl; two 
factor ANOVA; F<0.001; Bonferroni post-hoc tests). These results are shown in 
Figure 7.8. 
206 
7.2.3 Knee extension angle 
Knee extension angles that provoked struggling behaviour were not significantly 
different in FCA-injected knees of rats with and without low dose dexamethasone 
(0.01 mg/kg/day) treatment (n=4-8;戶〉0.05; two factor ANOVA). There was no 
significant difference between extension angles of their contralateral saline-injected 
knees (尸〉0.05; two factor ANOVA), but they required to be extended much greater 
than their respective FCA-injected knees to produce struggling behaviour from day 1 
onwards (P<0.001; two factor ANOVA;户<0.001; Bonferroni post-hoc tests). These 
results are shown in Figure 7.9. 
The FCA-injected knees with high dose dexamethasone treatment (0.1 mg/kg/day) 
required to be extended much greater than those without dexamethasone treatment to 
produce struggling behaviour (n=5-8;尸<0.01; two factor ANOVA); following 
dexamethasone treatment, the extension angle was larger from day 1 onwards (户<0.05, 
尸<0.01，P<0.001; Bonferroni post-hoc tests). Extension angles of their contralateral 
saline-injected knees were not significantly different (P>0.05; two factor ANOVA), 
but they required to be extended much greater than their respective FCA-injected 
knees to produce struggling behaviour from day 4 onwards (P>0.05; Bonferroni 
post-hoc tests). These results are shown in Figure 7.10. 
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Similarly, LS alleviated pain in the FCA-injected knees compared with those without 
LS treatment; following LS treatment, the extension angle required to provoke 
struggling behaviour was larger on days 3 and 7 (n=6-8; P<0.05; two factor ANOVA; 
P<0.01; Bonferroni post-hoc tests). Extension angles of the contralateral 
saline-injected knees of these two groups of animals were not significantly different 
(P>0.05; two factor ANOVA), but they required to be extended much greater than 
their respective FCA-injected knees to produce struggling behaviour from day 1 
onwards (PcO.OOl; two factor ANOVA; P<0.01, P<0.001; Bonferroni post-hoc tests). 
These results are shown in Figure 7.11. 
On the other hand, intra-peritoneal injection of saline did not alleviate pain; extension 
angles that provoked struggling behaviour in the FCA-injected knees were the same in 
rats with and without saline treatment (n=7-8; P�0.05; two factor ANOVA). 
Extension angles of the contralateral saline-injected knees in these two groups of 
animals were also not significantly different (P>0.05; two factor ANOVA), but they 
can be extended much greater than their respective FCA-injected knees to produce 
struggling behaviour from day 1 onwards (PcO.OOl; two factor ANOVA;尸<0.001; 
Bonferroni post-hoc tests). These results are shown in Figure 7.12. 
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7.2.4 Knee joint blood flow 
As shown in figure 7.13, a significant reduction in blood flow of the FCA-injected 
knees was found only after treatment with high doses of dexamethasone (0.1 
mg/kg/day; n=4-8; P<0.05; unpaired r-test) but not with low doses of dexamethasone 
(0.01 mg/kg/day;尸>0.05; unpaired r-test). Hyperaemia in the FCA-injected knees was 
also reduced by LS treatment (n=6-8; PcO.Ol; unpaired r-test), but saline treatment 
had no effect (n=8-9; P>0.05; unpaired r-test). 
7.2.5 Histological evaluation 
7.2.5.1 Cell infiltration 
As shown in Figure 7.15, the cell infiltration level in FCA-injected knees of rats with 
dexamethasone treatment (0.1 mg/kg/day) was significantly lower than that without 
dexamethasone treatment (n=4-8; P<0.001; paired r-test). LS also significantly 
reduced the cell infiltration level in FCA-injected knees (n=6-8; PcO.OOl; paired 
/-test). 
The contralateral saline-injected knees of rats with dexamethasone treatment showed 
lower cell infiltration level than those without dexamethasone treatment (PcO.OOl; 
paired r-test). There was no significant difference in cell infiltration level between 
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contralateral saline-injected knees of rats with and without LS treatment (P>0.05; 
paired Mest). These results were shown in the micrographs in Figure 7.14 and Figure 
7.15. 
7.2.5.2 Synovial tissue proliferation 
FCA-injected knees of rats with dexamethasone treatment (0.1 mg/kg/day) showed 
lower synovial tissue proliferation level than those without dexamethasone treatment 
(n=4-8; P<0.05; paired r-test). Similarly, LS significantly reduced synovial tissue 
proliferation level in FCA-injected knees (n=6-8; P<0.05; paired r-test). 
There was no significant difference in the level of synovial tissue proliferation 
between contralateral saline-injected knees of rats with and without dexamethasone 
treatment (P>0.05; paired r-test). Similar results were found in the contralateral 
saline-injected knees of rats with and without LS treatment (P>0.05; paired /-test). 
These results were shown in the micrographs in Figure 7.16 and Figure 7.17. 
7.2.5.3 Cartilage degradation 
As shown in Figure 7.19, there was significant difference in cartilage degradation 
level between FCA-injected knees of rats with and without high dose (0.1 mg/kg/day) 
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Dex treatment (n=4-8;尸<0.001; paired r-test); the Dex-treated group had reduced 
cartilage degradation. The cartilage degradation level of FCA-injected knees of rats 
treated with LS was also significantly lower than that without LS treatment (n=6-8; 
尸 < 0 . 0 0 1 ; paired r-test). 
There was no significant difference in cartilage degradation level between 
contralateral saline-injected knees of rats with and without dexamethasone treatment 
(P>0.05; paired 厂test). Similar results were found in the contralateral saline-injected 
knees of rats with and without LS treatment (P>0.05; paired r-test). These results were 
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Figure 7.1 
Effects of 14 days intra-peritoneal injection of dexamethasone on body weight in 
adjuvant-induced monoarthritic rats. Dexamethasone (0.01 mg/kg/day) was injected 
to the rats 7 days before and 7 days after induction of monoarthritis on day 0. There 
was no significant difference in body weight throughout the 15 days of experiment 
(尸〉0.05; one factor ANOVA). Data are shown as means 土 S.E.M. (shown by vertical 
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Figure 7.2 
Effects of 14 days intra-peritoneal injection of dexamethasone on body weight of 
adjuvant-induced monoarthritic rats. Dexamethasone (0.1 mg/kg/day) was injected to 
the rats 7 days before and 7 days after induction of monoarthritis on day 0. There was 
no significant difference in body weight throughout the 15 days of experiment 
(P>0.05; one factor ANOVA). Data are shown as means 土 S.E.M. (shown by vertical 
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Figure 7.3 
Effects of 14 days intra-peritoneal injection of LS on body weight of 
adjuvant-induced monoarthritic rats. LS (0.05 g/kg/day) was injected to the rats 7 
days before and 7 days after induction of monoarthritis on day 0. There was no 
significant difference in body weight throughout the 15 days of experiment (P�0.05; 
one factor ANOVA). Data are shown as means 士 S.E.M. (shown by vertical bars) of 
weight expressed in gram. 
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Figure 7.4 
Effects of 14 days intra-peritoneal injection of saline on body weight of 
adjuvant-induced monoarthritic rats. Saline (1 ml/kg/day) was injected to the rats 7 
days before and 7 days after induction of monoarthritis on day 0. The body weight 
showed a gradual increase and was significant on days -1, 0, 5, 6 and 7 (*P<0.05, 
**P<0.01, ***P<0.001; one factor ANOVA). Data are shown as means 土 S.E.M. 
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Figure 7.5 
Effects of 14 days intra-peritoneal injection of dexamethasone (Dex) on knee joint 
sizes of adjuvant-induced monoarthritic rats. Dex (0.01 mg/kg/day) was administered 
to the rats 7 days before and 7 days after induction of monoarthritis. There was no 
significant difference in knee joint sizes between FCA-injected knees of rats with and 
without Dex treatment (n=4-8; P>0.05; two factor ANOVA). Knee joint sizes of their 
contralateral saline-injected knees were also not significantly different ( P � 0 . 0 5 ; two 
factor ANOVA), but they were smaller than their respective FCA-injected knees 
(***P<0.001; two factor ANOVA). Bonferroni post-hoc tests: "^PcO.OOl 
(FCA-injected knees with Dex treatment vs their contralateral saline-injected knees). 
Data are shown as means 土 S.E.M. (shown by vertical bars) of knee joint sizes 




'S 50- t s . FCA + Dex (0.1 mg/kg/day) 
c 40- ^^ ®^ -OSal + Dex(0.1 mg/kg/day) *** • *• 
30. h #+/# r“ + ^ "^FCA ns 
o I Jh^^ T ### "O Sal 
I : / ^ " H ~ i 
§> 0- Q Q Q 
m 
sz - 1 0 -
O 
•20H 1 1 1 1 1 1 1 1 1 
-1 0 1 2 3 4 5 6 7 8 
Days post FCA injection 
Figure 7.6 
Effects of 14 days intra-peritoneal injection of dexamethasone (Dex) on knee joint 
sizes of adjuvant-induced monoarthritic rats. Dex (0.1 mg/kg/day) was administered 
to the rats 7 days before and 7 days after induction of monoarthritis. There was 
significant difference in knee joint sizes between FCA-injected knees of rats with and 
without Dex treatment; the former had reduced swelling (n=5-8; ***P<0.001; two 
factor ANOVA), but were still more swollen than their contralateral saline-injected 
knees (**尸<0.01; two factor ANOVA). There was no significant difference in knee 
joint sizes between contralateral saline-injected knees of rats with and without Dex 
treatment (P>0.05; two factor ANOVA). Bonferroni post-hoc tests: •P<0.001 
(FCA-injected knees with Dex treatment vs without); +P<0.05，付PcO.Ol, + 付尸<0.001 
(FCA-injected knees with Dex treatment vs their contralateral saline-injected knees). 
Data are shown as means 土 S.E.M. (shown by vertical bars) of knee joint sizes 
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Figure 7.7 
Effects of 14 days intra-peritoneal injection of LS on knee joint sizes of 
adjuvant-induced monoarthritic rats. LS (0.05 g/kg/day) was administered to the rats 7 
days before and 7 days after induction of monoarthritis. There was significant 
difference in knee joint sizes between FCA-injected knees of rats with and without LS 
treatment; the former had reduced swelling (n=6-8; ***P<0.001; two factor ANOVA), 
but were still more swollen than their contralateral saline-injected knees (***P<0.001; 
two factor ANOVA). There was no significant difference in knee joint sizes between 
contralateral saline-injected knees of rats with and without LS treatment (P>0.05; two 
factor ANOVA). Bonferroni post-hoc tests:漏PcO.OOl (FCA-injected knees with LS 
treatment vs without); +++尸<0.001 (FCA-injected knees with LS treatment vs their 
contralateral saline-injected knees). Data are shown as means 土 S.E.M. (shown by 
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Figure 7.8 
Effects of 14 days intra-peritoneal injection of saline on knee joint sizes of 
adjuvant-induced monoarthritic rats. Saline (1 ml/kg/day) was administered to the rats 
7 days before and 7 days after induction of monoarthritis. There was no significant 
difference in knee joint sizes between FCA-injected knees of rats with and without 
saline treatment (n=7-8;尸〉0.05; two factor ANOVA). Knee joint sizes of their 
contralateral saline-injected knees were also not significantly different ( P � 0 . 0 5 ; two 
factor ANOVA), but they were smaller than their respective FCA-injected knees 
(***P<0.001; two factor ANOVA). Bonferroni post-hoc tests: +++P<0.001 
(FCA-injected knees with saline treatment vs their contralateral saline-injected knees). 
Data are shown as means 土 S.E.M. (shown by vertical bars) of knee joint sizes 
expressed in percentage change. 
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Figure 7.9 
Effects of 14 days intra-peritoneal injection of Dex on knee extension angles that 
provoked struggling behaviour in adjuvant-induced monoarthritic rats. Dex (0.01 
mg/kg/day) was administered to the rats 7 days before and 7 days after induction of 
monoarthritis. There was no significant difference in knee extension angles that 
provoked struggling behaviour in FCA-injected knees of rats with and without Dex 
treatment (n=4-8; P>0.05; two factor ANOVA). Extension angles of their 
contralateral saline-injected knees were also not significantly different ( P � 0 . 0 5 ; two 
factor ANOVA), but they required to be extended much greater than their respective 
FCA-injected knees to produce struggling behaviour (***P<0.001; two factor 
ANOVA). Bonferroni post-hoc tests: V<0.05 (FCA-injected knees with Dex 
treatment vs without); "^十尸<0.001 (FCA-injected knees with Dex treatment vs their 
contralateral saline-injected knees). Data are shown as means 土 S.E.M. (shown by 
vertical bars) of changes in extension angle expressed in percentage change. 
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Figure 7.10 
Effects of 14 days intra-peritoneal injection of Dex on knee extension angles that 
provoked struggling behaviour in adjuvant-induced monoarthritic rats. Dex (0.1 
mg/kg/day) was administered to the rats 7 days before and 7 days after induction of 
monoarthritis. There was significant difference in knee extension angles that 
provoked struggling behaviour in FCA-injected knees of rats with and without Dex 
treatment (n=5-8; ••PcO.Ol; two factor ANOVA). Extension angles of their 
contralateral saline-injected knees were not significantly different (P>0.05; two factor 
A N O V A ) , but they required to be extended much greater than their respective 
FCA-injected knees to produce struggling behaviour (*P<0.05; two factor ANOVA). 
Bonferroni post-hoc tests: #P<0 .05 ,胖P<0.01 ,醒PcOWl (FCA-injected knees with 
Dex treatment vs without); +P<0.05, ++/^<0.01 (FCA-injected knees with Dex 
treatment vs their contralateral saline-injected knees). Data are shown as means 土 
S.E.M. (shown by vertical bars) of changes in extension angle expressed in 
percentage change 
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Figure 7.11 
Effects of 14 days intra-peritoneal injection of LS on knee extension angles that 
provoked struggling behaviour in adjuvant-induced monoarthritic rats. LS (0.05 
g/kg/day) was administered to the rats 7 days before and 7 days after induction of 
monoarthritis. There was significant difference in knee extension angles that 
provoked struggling behaviour in FCA-injected knees of rats with and without LS 
treatment (n=6-8; *尸<0.05; two factor ANOVA). Extension angles of their 
contralateral saline-injected knees were not significantly different (P>0.05; two factor 
ANOVA), but they required to be extended much greater than their respective 
FCA-injected knees to produce struggling behaviour (***P<0.001; two factor 
ANOVA). Bonferroni post-hoc tests: ^V<0.01 (FCA-injected knees with LS 
treatment vs without); '^P<0.01, +++i^<0.001 (FCA-injected knees with LS treatment 
vs their contralateral saline-injected knees). Data are shown as means 土 S.E.M. 
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Figure 7.12 
Effects of 14 days intra-peritoneal injection of saline on knee extension angles that 
provoked struggling behaviour in adjuvant-induced monoarthritic rats. Saline (1 
ml/kg/day) was administered to the rats 7 days before and 7 days after induction of 
monoarthritis. There was no significant difference in knee extension angles that 
provoked struggling behaviour in FCA-injected knees of rats with and without saline 
treatment (n=7-8; P>0.05; two factor ANOVA). Extension angles of their 
contralateral saline-injected knees were also not significantly different ( P � 0 . 0 5 ; two 
factor ANOVA), but they required to be extended much greater than their respective 
FCA-injected knees to produce struggling behaviour (***P<0.001; two factor 
ANOVA). Bonferroni post-hoc tests: ^"'P<0.001 (FCA-injected knees with saline 
treatment vs their contralateral saline-injected knees). Data are shown as means 土 
S.E.M. (shown by vertical bars) of changes in extension angle expressed in 
percentage change. 
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Figure 7.13 
Effects of 14 days intra-peritoneal injection of Dex, LS or saline on knee joint blood 
flow of adjuvant-induced monoarthritic rats. Dex (0.01 mg/kg/day or 0.1 mg/kg/day), 
LS (0.05 g/kg/day) or saline (1 ml/kg/day) was injected to the rats 7 days before and 7 
days after induction of monoarthritis. A significant reduction in blood flow was found 
with the administration of high doses of Dex (0.1 mg/kg/day) (n=5-8; *P<0.05; 
two-factor ANOVA) but not with low doses of Dex (0.01 mg/kg/day) (n=4-8; P�0.05; 
two-factor ANOVA). LS treatment also reduced blood flow in the inflamed knee 
joints (n=6-8; **戶<0.01; two-factor ANOVA), but saline treatment had no effect 
(n=7-8; P>0.05; two-factor ANOVA). Data are shown as means 土 S.E.M. (shown by 
vertical bars) of changes in blood flow expressed in flux. 
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Figure 7.14 
Cell infiltration in synovial tissues of FCA-injected test knees (A) and saline-injected 
contralateral knees (B) of rats without intra-peritoneal treatment (control) (a), and 
with 14 days intra-peritoneal injection of 0.01 mg/kg/day Dex (b), 0.1 mg/kg/day Dex 
(c), 0.05 g/kg/day LS (d), and 1 ml/kg/day saline (e). Magnification = 5X. 
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Figure 6.3.15 
Effects of 14 days intra-peritoneal injection of Dex, LS or saline on cell infiltration in 
synovial tissues of FCA-injected test knees (A) and saline-injected contralateral knees 
of rats (B). Intra-peritoneal injections of drugs were given daily. Compared with 
control rats that had no intraperitoneal treatment, there was a significant decrease in 
cell infiltration level in FCA-injected knees of rats with high dose Dex (n=4-8; 
***P<0.001; paired Mest) and LS (n=6-8; ***P<0.001; paired r-test) treatments. Cell 
infiltration levels in contralateral saline-injected knees of rats treated with low and 
high dose Dex were also reduced compared with control (n=4-8; **P<0.01 and 
***尸<0.001, respectively; paired r-test). 
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Figure 7.16 
Synovial tissue proliferation of FCA-injected test knees (A) and saline-injected 
contralateral knees (B) of rats without intra-peritoneal treatment (control) (a), and 
with 14 days intra-peritoneal injection of 0.01 mg/kg/day Dex (b), 0.1 mg/kg/day Dex 
(c), 0.05 g/kg/day LS (d), and 1 ml/kg/day saline (e). Magnification = 2.5X. 
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Effects of 14 days intra-peritoneal injection of Dex, LS or saline on synovial tissue 
proliferation of FCA-injected test knees (A) and saline-injected contralateral knees of 
rats (B). Intra-peritoneal injections of drugs were given daily. Compared with control 
rats that had no intraperitoneal treatment, there were significant reductions in synovial 
tissue proliferation in FCA-injected knees of rats treated with high dose Dex (n=4-8; 
*P<0.05; paired r-test) and LS (n=6-8; *P<0.05; paired r-test). There was no 
significant difference in synovial tissue proliferation level between contralateral 
saline-injected knees of rats treated with LS compared with control (n=6-8; P>0.05; 
paired r-test) or Dex treatment (n=4-8; P>0.05; paired r-test). 
232 
(A) FCA-injected (test) knees (B) Saline-injected (contralateral) knees 
(a) FCA (a) Saline 
(b) Dex (0.01 mg/kg/day) (b) Dex (0.01 mg/kg/day) 
B M 
(c) Dex (0.1 mg/kg/day) (c) Dex (0.1 mg/kg/day) 
K M 
(d) LS (0.05 g/kg/day) (d) LS (0.05 g/kg/day) 
mm 
233 
(e) Saline (1 ml/kg/day) (e) Saline (1 ml/kg/day) 
MM 
Figure 7.18 
Cartilage degradation of FCA-injected test knees (A) and saline-injected contralateral 
knees (B) of rats without intra-peritoneal treatment (control) (a), and with 14 days 
intra-peritoneal injection of 0.01 mg/kg/day Dex (b), 0.1 mg/kg/day Dex (c), 0.05 
g/kg/day LS (d), and 1 ml/kg/day saline (e). Magnification = 5X. 
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Figure 6.3.15 
Effects of 14 days intra-peritoneal injection of Dex, LS or saline on cartilage 
degradation of FCA-injected test knees (A) and saline-injected contralateral knees (B) 
of rats. Intra-peritoneal injections of drugs were given daily. Compared with control 
rats that had no intraperitoneal treatment, there were significant reductions in cartilage 
degradation in FCA-injected knees of rats treated with high dose Dex (n=4-8; 
•••P<0.001; paired r-test) and LS (n=6-8; •**尸<0.001; paired r-test). Contralateral 
saline-injected knees of all treatment groups showed negligible cartilage degradation 
(n=4-8;尸〉0.05 for all; paired r-test). 
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7.3 Discussions 
TCM is commonly taken by the oral route. However, the hepatic first-pass effect may 
cause low bioavailability even when a drug is well absorbed. Injection of drugs 
usually produces a faster and better effect than oral administration. The antiarthritis 
efficacy of LS given by the intra-peritoneal route is uncertain. Therefore, 
intra-peritoneal treatment of LS on the adjuvant-induced monoarthritis model was 
investigated. 
As discussed earlier, LS was proven to be effective in alleviating arthritic symptoms 
when given to rats daily by the oral route for 7 days before and 7 days after induction 
of arthritis. In the present study, the same approach was used for intra-peritoneal 
treatment of LS (0.05 g/kg/day) for comparison. Like that of oral administration, 
intra-peritoneal injection of LS for 14 days dramatically reduced swelling, pain and 
hyperaemia in the FCA-injected knees. Histological examination further revealed that 
LS ameliorated infiltration of inflammatory cells, synovial tissue proliferation and 
erosion of cartilage in the arthritic joints. These findings confirmed that LS possesses 
anti-inflammatory and analgesic effects when given intra-peritoneally. 
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The analgesic effect of LS may be associated with ganoderic acids A, B, G and H and 
compound C6 from Ganoderma lucidum (one of the components of LS) which were 
shown to have antinociceptive effects (Koyama et al., 1997). 
Oral treatment of LS given by the same protocol did not reduce pain and tissue 
proliferation in the arthritic joints. Therefore, intra-peritoneal treatment of LS 
provided better anti-arthritis efficacy as it reduced all arthritic symptoms in the 
affected joints. This finding is expected since intra-peritoneal administration of LS 
would provide better systemic absorption of the drug and it would avoid the hepatic 
first pass effect of oral administration that reduces the bioavailability of LS for local 
actions in the knee joint. Nonetheless, although intra-peritoneal injection of LS 
provides better anti-inflammatory and analgesic efficacies, it is not a preferable or 




Nowadays, there is a growing interest internationally in the use of traditional Chinese 
medicine (TCM) (Davidson et aL, 2003; Pach et al., 2002). TCM is perceived as a 
more natural and potentially safer alternative in the treatment of chronic illnesses than 
modem Western drugs or surgery (Davidson et aL, 2003). Thus, it has become an 
important category of complementary and alternative medicine (CAM) in Western 
countries in the past decade (Chen et al., 2007; Eskinazi, 1998). However, scientific 
evaluation of the therapeutic efficacy and mechanisms of actions of many of the TCM 
are still inadequate. 
Animal models can be used to mimic disease conditions without the use of human 
subjects. Therefore, they are very important in preclinical studies of new drugs to 
predicate their possible benefits and risks before human administration. In the present 
study, an adjuvant-induced arthritic rat model was used. Single unilateral injection of 
FCA produced significant oedema, algesia, hyperaemia, immune cell infiltration, 
synovial tissue proliferation, and erosion of cartilage in ipsilateral FCA-injected (test) 
knees compared with contralateral saline-injected (control) knees. This study 
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successfully produced discrete monoarthritis in the rat knee joint that shared several 
clinical and pathological features of the human disease, and this provided a useful 
platform for the testing of potential new anti arthritic agents. 
A Lingzhi and Sen Miao San capsule (LS), which is composed of Ganoderma 
lucidum, Cortex Phellodendri, Atractylodisa Rhizoma and Radix Achyranthis 
Bidentatae. These constituents of LS are reported to have anti-inflammatory and 
analgesic effects, but the efficacy of LS in treatment of arthritic diseases is unknown. 
Therefore, its anti-arthritic property was investigated in the adjuvant-induced 
monoarthritic rats. 
Administration of drugs by injection usually produces a faster on set of action than by 
the oral route. Injection of drugs at their local site of action also minimizes systemic 
side effects (Furtado et al., 2005; Schumacher et al., 2005). Therefore, local 
intra-articular injection of LS into the rat knee was investigated. Ipsilateral 
intra-articular injection of LS (2.5 mg/kg/day) for 2 consecutive days after the 
induction of arthritis was found to be inappropriate for treatment of arthritis as it did 
not alleviate arthritis symptoms but produced further damage of the inflamed joints 
leading to more severe inflammation. 
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Traditional Chinese medicines are commonly taken orally. The Lingzhi and Sen Miao 
San (LS) formulation used in the present study is in the form of capsule for oral 
administration. In order to mimic the actual therapeutic oral route of administration, 
the antiarthritis efficacy of oral administration of LS was investigated in the present 
study. Oral administration of LS (500 mg/kg/day and 1000 mg/kg/day) for 7 days 
after the induction of arthritis did not improve the arthritis symptoms. The same 
negative finding was obtained with oral administration of LS (500 mg/kg/day of LS) 
extended to 13 days. Interestingly, oral administration of LS (500 mg/kg/day) for 7 
days before induction of arthritis (prophylactic treatment) and 7 days after induction 
of arthritis (therapeutic treatment) suppressed oedema (P < 0.05) and hyperaemia (P < 
0.01) in the inflamed knee. Moreover, histological examination showed that this 
protocol of oral administration of LS reduced immune cell infiltration {P < 0.001 for 
both), and erosion of cartilage (P < 0.001 for both) in the inflamed knee. Therefore, it 
can be concluded that LS possesses better antiarthritic efficacy when administered 
prophylactically, i.e. before the induction of arthritis. 
Injection of drugs usually produces a faster and better effect than oral administration 
as the hepatic first-pass effect may cause low bioavailability even when a drug is well 
absorbed. Therefore, intra-peritoneal treatment of LS on the adjuvant-induced 
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monoarthritis model was evaluated. Oedema (P < 0.001), pain (P < 0.05), hyperaemia 
(P < 0.01), and synovial tissue proliferation (P < 0.05) were suppressed in the 
inflamed knees when LS (50 mg/kg/day) was injected intra-peritoneally for 7 days 
before and 7 days after induction of arthritis. These findings suggest a combination of 
7 days prophylactic treatment plus 7 days therapeutic treatment with intra-peritoneal 
or oral LS could provide significant anti-arthritic effects. 
The mechanisms for the antiarthritic effects of LS are still unknown. Some studies 
have shown that the anti-arthritic effects of several Chinese herbal products involved 
inhibition of the local tissue cytokine pathways (Fan et al., 2005; Ho et al” 1999; Shin 
et al., 2003; Yeom et al., 2003). Whether the protective effects of LS in the present 
arthritis model are also due to inhibition of cytokine activities is uncertain, and it will 
have to be elucidated by further experiments. 
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